{"text": "Omalizumab was to be administered subcutaneously at a dose normalized for body mass and serum IgE level , approximately 0.016 mg / kg / IgE [ IU / ml ] per month .", "label": "", "metadata": {}, "score": "29.861256"}
{"text": "During the first time , 150 mg / dose of omalizumab was administered at 4-week intervals , according to the pretreatment IgE concentration .", "label": "", "metadata": {}, "score": "31.82734"}
{"text": "Doses were determined based on weight and total IgE levels as per Omalizumab Global Dosing schedule as outlined in the online supplement ( Additional file 1 : Table S1 ) .", "label": "", "metadata": {}, "score": "31.858925"}
{"text": "Thus , the dose of omalizumab was increased to 300 mg on the concentration basis of IgE measured before steroid therapy .After increasing the doses , the symptoms improved significantly , and the therapeutic effect was maintained .", "label": "", "metadata": {}, "score": "34.061172"}
{"text": "In the present case , the pretreatment IgE concentration was 97.4 IU / mL , which was rounded to 100 IU / mL , and the dose of 150 mg was selected first ; however , the dose was later increased to 300 mg to obtain a better result .", "label": "", "metadata": {}, "score": "40.111744"}
{"text": "Combined with food OIT , omalizumab is posited to increase dose tolerability , thus allowing for the possibility of a higher initial starting dose and faster treatment progression .", "label": "", "metadata": {}, "score": "40.697556"}
{"text": "Omalizumab has been available for CSU through carefully controlled and monitored clinical trials .These trials are designed to better understand the potential benefits and risks of the compound .", "label": "", "metadata": {}, "score": "41.3926"}
{"text": "No text entered .Reporting Groups .Description .Omalizumab ( Placebo in Q2788 g ) .Either a minimum of 0.016 mg / kg / IgE ( IU / mL ) every 4 weeks or 0.008 mg / kg / IgE ( IU / mL ) every 2 weeks ( based on dosing table ) .", "label": "", "metadata": {}, "score": "41.41497"}
{"text": "Omalizumab ( Xolair ) was administered subcutaneously every 2 or 4 weeks .The dose ( mg ) and dosing frequency were determined by serum total IgE level ( IU / mL ) , measured before the start of treatment , and body weight ( kg ) .", "label": "", "metadata": {}, "score": "42.195564"}
{"text": "Three subjects had total serum IgE slightly greater than 1500 kUa / L and received the maximum dose of Omalizumab ( 600 mg every 2 weeks ) .", "label": "", "metadata": {}, "score": "43.72962"}
{"text": "This treatment option is limited to patients with baseline IgE level of 30 to 1.500 IU / ml and body weight of 20 to 150 kg .", "label": "", "metadata": {}, "score": "43.751396"}
{"text": "There were to be several phases : 4-week run - in , 1-week baseline , 12-week phase with stable corticosteroid dosing , 8-week treatment phase with protocol - defined corticosteroid tapering , and a final 10-week safety period after the last dose of omalizumab was administered ( Figure 2 ) .", "label": "", "metadata": {}, "score": "43.838932"}
{"text": "He said two other phase III trials had also been conducted , with analysis still underway .Among other things , these trials tested omalizumab with antihistamines given at the higher unlicensed doses that are currently the standard in routine practice , Casale said .", "label": "", "metadata": {}, "score": "43.94401"}
{"text": "It is then measured at about 12 minutes into each exercise period .Omalizumab : Dosing for omalizumab will be consistent with doses approved for use in moderate or severe allergic asthma .", "label": "", "metadata": {}, "score": "45.126873"}
{"text": "safety - evaluable population .Reporting Groups .Description .Omalizumab ( Placebo in Q2788 g ) .Either a minimum of 0.016 mg / kg / IgE ( IU / mL ) every 4 weeks or 0.008 mg / kg / IgE ( IU / mL ) every 2 weeks ( based on dosing table ) .", "label": "", "metadata": {}, "score": "45.383316"}
{"text": "Although there is currently no cure , oral immunotherapy ( OIT ) is under investigation .Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen protein .", "label": "", "metadata": {}, "score": "45.498863"}
{"text": "After obtaining pharmacodynamic data using basophil assays and free IgE measurements in subjects with food allergies who received standard omalizumab dosing , we found that 8 weeks post standard omalizumab therapy is an optimal time to start oral immunotherapy [ 46 , 47 ] .", "label": "", "metadata": {}, "score": "45.58607"}
{"text": "In order to evaluate the efficacy of omalizumab , the Global Evaluation of Treatment Effectiveness scales ( GETE )[ 3 , 9 , 10 ] was used and the result was good .", "label": "", "metadata": {}, "score": "45.721836"}
{"text": "The nature and extent of the discontinuations would not be expected to influence the overall judgment of the effect of omalizumab in this trial .Analyses of trial results were performed by Genentech at the end of the stable steroid and steroid reduction phases prior to full completion of study .", "label": "", "metadata": {}, "score": "45.72705"}
{"text": "This might be relevant from a pharmaco - economic perspective .This could possibly offset the cost of omalizumab at the current time , which varies between $ 2,164 and $ 10,824 for 16 weeks , depending on the patient 's weight and total IgE levels .", "label": "", "metadata": {}, "score": "46.02205"}
{"text": "Pre - treatment with omalizumab .Omalizumab injections were administered at the hospital 's Clinical Translational Food Unit ( CTFU ) under medical supervision and patients were observed for at least one hour after injection .", "label": "", "metadata": {}, "score": "46.21852"}
{"text": "There were no deaths or cases of anaphylactic shock .Casale and colleagues concluded that omalizumab at 150 or 300 mg was effective at reducing urticaria , but also that \" the number of patients who were treated was too small to draw any definitive safety conclusions .", "label": "", "metadata": {}, "score": "46.6848"}
{"text": "More placebo subjects discontinued for lack of therapeutic effect as in 008 , but the discrepancy between placebo and omalizumab was not as great .Reasons for withdrawal of consent were primarily not illness - related .", "label": "", "metadata": {}, "score": "48.2743"}
{"text": "In the US , Xolair ( omalizumab ) for subcutaneous use in appropriate allergic asthma patients is co - promoted by Novartis Pharmaceuticals Corporation and Genentech , Inc. .", "label": "", "metadata": {}, "score": "48.413475"}
{"text": "This was a double - blind comparison of 2 dose levels of omalizumab to placebo in 504 subjects 12 - 45 years old with asthma requiring corticosteroid treatment .", "label": "", "metadata": {}, "score": "48.45835"}
{"text": "Omalizumab was effective in reducing the numbers of subjects with exacerbations in both treatment schedules .Brand Names : U.S. .Xolair .Pharmacologic Category .", "label": "", "metadata": {}, "score": "48.48744"}
{"text": "Introduction .The anti - immunoglobulin E ( IgE ) monoclonal antibody omalizumab was approved in 2005 , by the European Medicines Agency for the treatment of severe asthma [ 1 ] .", "label": "", "metadata": {}, "score": "48.614807"}
{"text": "Based on these considerations , we hypothesized that treatment with omalizumab in our patient could be effective , in spite of what is indicated by the guidelines and the manufacturer .", "label": "", "metadata": {}, "score": "48.952705"}
{"text": "IgE within the following ranges and body weights for subcutaneous omalizumab dosing : . units / mL : 30 - 90 kg : 150 mg every 4 weeks .", "label": "", "metadata": {}, "score": "49.148403"}
{"text": "Contraindications .Severe hypersensitivity reaction to omalizumab or any component of the formulation .Dosage .Dosing should be adjusted during therapy for significant changes in body weight .", "label": "", "metadata": {}, "score": "49.914474"}
{"text": "At any given time , the prevalence of CSU is 0.5 % to 1 % worldwide6 .Omalizumab is being jointly developed by Novartis and Genentech , Inc. for CSU .", "label": "", "metadata": {}, "score": "49.9562"}
{"text": "Trial Q0694 g was a trial comparing two doses of omalizumab to placebo .Its design was similar to that of the subsequent pivotal trials 008 , 009 , and 010 .", "label": "", "metadata": {}, "score": "50.035767"}
{"text": "Comment .The reduction in oral corticosteroid dosing was not seen in trial 011 , which randomized 100 subjects to placebo or to the proposed regimen of omalizumab in a subcutaneous dosing . \u00b7", "label": "", "metadata": {}, "score": "50.220543"}
{"text": "Subsequently , the steroid dosage was reduced ; however , her asthma was poorly controlled , and symptoms of otorrhea and hearing worsened .Omalizumab ( Novartis Pharma K.K. , Tokyo , Japan ) treatment for severe asthma was started from December 12 , 2009 .", "label": "", "metadata": {}, "score": "50.25419"}
{"text": "A serendipitous observation several years ago prompted interest in omalizumab as a potential alternative .Clinicians noticed that the drug , which is approved for preventing allergic asthma exacerbations , appeared to clear up chronic urticaria in asthma patients who had both conditions .", "label": "", "metadata": {}, "score": "50.348454"}
{"text": "J Invest Dermatol .2005 Oct;125(4):659 - 64 .European Medicines Evaluation Agency .Omalizumab ( XOLAIR ) .Summary of product characteristics .Accessed 7 June , 2013 .", "label": "", "metadata": {}, "score": "50.485855"}
{"text": "Omalizumab was to be supplied as a lyophilate containing 150 mg omalizumab , 108 mg sucrose , 1.3 mg L - histidine , 2.1 mg L - histidine HCl monohydrate , and 0.4 mg polysorbate 20 .", "label": "", "metadata": {}, "score": "51.453278"}
{"text": "The placebo is an injection of inert physiological saline ( \" salt water \" ) which contains no omalizumab .Detailed Description .Randomization of cohorts for study ( SC ) : .", "label": "", "metadata": {}, "score": "52.022438"}
{"text": "On the 9 th week after the 1 st injection of omalizumab , the participants underwent rapid oral desensitization to up to five offending food allergens ( Figure 1 ) .", "label": "", "metadata": {}, "score": "52.15164"}
{"text": "Comment .The dosing choices included a dose similar to the 0.016 mg / kg / IU [ IgE ] every 4 weeks proposed for marketing ( 0.012 mg / kg / IU [ IgE ] every 4 weeks ) and one approximately twice the proposed marketed dose ( 0.028 mg / kg / IU [ IgE ] every 4 weeks ) .", "label": "", "metadata": {}, "score": "52.2511"}
{"text": "The highest tolerated dose ( i.e. with no clinical reactivity ) determined the participant 's starting daily home dose ( up to a total dose of 1250 mg protein , divided evenly into each of the separate offending food allergens ) .", "label": "", "metadata": {}, "score": "52.33927"}
{"text": "This is consistent with one of the key long term goals of the study which was to begin to develop customized , patient - based , regimens for oral immunotherapy that could be tested for safety , and dose tolerability .", "label": "", "metadata": {}, "score": "52.38006"}
{"text": "\" The significant improvements observed with omalizumab were sustained throughout the treatment period up to Week 241 .The study also evaluated impact on quality of life , an important measure as up to 80 % of patients with CSU suffer negative effects on their quality of life including sleep deprivation and psychological comorbidities such as depression and anxiety6 .", "label": "", "metadata": {}, "score": "52.45948"}
{"text": "Safety data are reviewed in another document .The proposed indication statement for omalizumab is : .XOLAIR is indicated as maintenance therapy for the prophylaxis of asthma exacerbations and control of symptoms in adults and adolescents ( 12 years and above ) with moderate to severe allergic asthma that is inadequately controlled despite the use of inhaled corticosteroids .", "label": "", "metadata": {}, "score": "52.497177"}
{"text": "To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protocol using omalizumab to allow for a faster and safe desensitization to multiple foods simultaneously .", "label": "", "metadata": {}, "score": "52.517597"}
{"text": "But mystery still remains - some patients in the trial showed substantial improvement within days of starting omalizumab .\" There is a function of this allergic [ non - IgE ] antibody that we do not yet understand , \" Kaplan said .", "label": "", "metadata": {}, "score": "52.8945"}
{"text": "Total serum IgE level \u00a3 1785 IU / ml .Skin reactivity to two or more different allergens to which there would be exposure during trial .", "label": "", "metadata": {}, "score": "53.06101"}
{"text": "13223_2013_415_MOESM1_ESM.docx Additional file 1 : Table S1 : Omalizumab dosing according to weight and total IgE levels .Table S2 .Food combinations .( DOCX 23 KB ) .", "label": "", "metadata": {}, "score": "53.091686"}
{"text": "The placebo for this study is inert physiologic saline ( \" salt water \" ) which contains no omalizumab .Both the omalizumab and the placebo will be administered as an injection under the skin .", "label": "", "metadata": {}, "score": "53.144882"}
{"text": "The design of medication standardization with a common corticosteroid and rescue b -agonist , determination of a corticosteroid dose acceptable to the subject and investigator , followed by a stable steroid phase and a subsequent steroid reduction phase , was copied in the pivotal trials .", "label": "", "metadata": {}, "score": "53.3122"}
{"text": "This process was modified in 1999 to produce the to - be - marketed product .The to - be - marketed product was used in open - label trials Q2143 g and IA04 .", "label": "", "metadata": {}, "score": "53.318733"}
{"text": "Clinical tolerance is proven by demonstrating sustained unresponsiveness to the food after stopping the maintenance dose for a prolonged period of time .Future phase 2 trials on the use of omalizumab combined with OIT will be useful to see if omalizumab affects this outcome .", "label": "", "metadata": {}, "score": "53.495407"}
{"text": "Most patients experienced at least one adverse event , although the total numbers were similar in all treatment arms .Over the entire 28-week study period , nine adverse events were rated as serious , including five in the 300-mg omalizumab group .", "label": "", "metadata": {}, "score": "53.794586"}
{"text": "Maurer M , Staubach P , Ashby M , et al .The safety and efficacy of omalizumab in chronic idiopathic / spontaneous urticaria ( CIU / CSU ) : results from a Phase III randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "53.883625"}
{"text": "Currently , omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy .Case presentation .We studied a 52-year - old man who has been suffering from severe non allergic steroid - resistant asthma with increased levels of total IgE and a lot of comorbidity .", "label": "", "metadata": {}, "score": "54.067112"}
{"text": "Both the pooled placebo groups and omalizumab groups improved during the trial .The difference from placebo in the change in symptom score was very small , approximately 0.5 symptom score units , consistent with the magnitude of changes seen in the critical efficacy trials .", "label": "", "metadata": {}, "score": "54.248814"}
{"text": "Product and placebo were supplied as lyophilates to be reconstituted with water for injection , 2 ml .The dose was titrated upward in the first week .", "label": "", "metadata": {}, "score": "54.293793"}
{"text": "The use of IgE immunomodulatory therapies , including monoclonal antibodies and small molecules , has been under investigation in food allergies and has been reviewed recently in the literature [ 37 - 45 ] .", "label": "", "metadata": {}, "score": "54.360687"}
{"text": "Dosing in a given cell of the table was calculated to provide 0.016 mg / kg / IgE for the maximal body mass and serum IgE level that the cell referred to ; that is , most subjects were to receive more than the idealized normalized dose .", "label": "", "metadata": {}, "score": "54.518448"}
{"text": "Completed core period , did not enter extension but completed follow - up period .The proportion of discontinuations in the placebo arm during the stable steroid phase of each trial was close to 10 % , and a further 4 - 5 % during the steroid reduction phase ; corresponding reductions in the omalizumab group were around 5 % and 2 % .", "label": "", "metadata": {}, "score": "54.982178"}
{"text": "The patient signed the informed consent and started the treatment in July 2006 ( 300 mg every 15 days subcutaneously ) .An improvement in symptoms of asthma control was evident after only 16 weeks of treatment ; the patient had no exacerbation .", "label": "", "metadata": {}, "score": "55.34353"}
{"text": "Omalizumab reduced the score by nearly 10 points by Week 12 , lowering the DLQI score to 2.3 .This signified a marked improvement in patients ' quality of life7 .", "label": "", "metadata": {}, "score": "55.529064"}
{"text": "Dosing level of an inhaled steroid must be consistent with mild episodic asthma as outlined by the NHLBI NAEPP guidelines .Any dose of inhaled steroid typically used for moderate or severe asthma will result in exclusion from the protocol .", "label": "", "metadata": {}, "score": "55.73819"}
{"text": "They were trained on the use of self - injectable epinephrine .Participants were instructed to avoid physical exertion 1 hour before and 2 hours after dosing and to contact the on - call service in the event of infection or environmental allergies .", "label": "", "metadata": {}, "score": "55.799656"}
{"text": "The drug 's recommended adult dose for asthma prophylaxis is 150 to 375 mg every 2 to 4 weeks .Patients remained on antihistamines if they and the treating physicians wanted them to , but only at the label - recommended doses .", "label": "", "metadata": {}, "score": "55.888893"}
{"text": "Conclusion .Our case shows , after a long follow - up , how omalizumab can be effective in a severe form of non - atopic asthma .", "label": "", "metadata": {}, "score": "56.13742"}
{"text": "Omalizumab discontinuation .Omalizumab treatment was discontinued 8 weeks after the initial escalation day of food allergens , totaling 16 weeks total of omalizumab treatment .", "label": "", "metadata": {}, "score": "56.161465"}
{"text": "References .Global Initiative for Asthma , 2005 .S. Holgate , T. Casale , S. Wenzel , J. Bousquet , Y. Deniz , and C. Reisner , \" The anti - inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation , \" Journal of Allergy and Clinical Immunology , vol .", "label": "", "metadata": {}, "score": "56.19996"}
{"text": "Inclusion and exclusion criteria were designed to ensure that subjects were within given IgE and weight ranges so that they could be dosed according to the dosing table provided .", "label": "", "metadata": {}, "score": "56.46776"}
{"text": "Finally , the assay of serum IgE at the end of follow - up was 419 IU / ml , with an increase compared to baseline .", "label": "", "metadata": {}, "score": "56.660294"}
{"text": "Elevated serum IgE levels for reasons other than atopia ( e.g. , parasitic infections , hyperimmunoglobulin E syndrome , allergic bronchopulmonary aspergillosis ) .Currently taking allergy vaccination therapy ( desensitization immunotherapy ) , with less than 3 months of stable maintenance doses prior to Visit 1 .", "label": "", "metadata": {}, "score": "56.68471"}
{"text": "Actually , one only report [ 11 ] concerns the effectiveness of this drug in a patient with non - allergic asthma ( who had high total IgE ) .", "label": "", "metadata": {}, "score": "56.688362"}
{"text": "g. Requiring treatment with inhaled corticosteroids in doses equivalent to beclomethasone 420 to 84 0 m g per day , for \u00b3 3 months prior to randomization ; and as needed or regular use of bronchodilator therapy .", "label": "", "metadata": {}, "score": "57.036434"}
{"text": "Phase 2 randomized controlled trials are needed to better define safety and efficacy parameters of multi OIT experimental treatments with and without omalizumab .Keywords .", "label": "", "metadata": {}, "score": "57.239777"}
{"text": "Antihistamines , inhaled beta-2 agonists , prednisolone , and injectable epinephrine were all readily available at the bedside .Food allergens were given over a period of 2.5 hours as outlined in Table 1 .", "label": "", "metadata": {}, "score": "57.3059"}
{"text": "Subjects were restricted in their use of concomitant medications , as was the case in the critical efficacy trials .Subjects were permitted only terfenadine ( Seldane ) and beclomethasone nasal spray ( Vancenase ) for the relief of symptoms of allergic rhinitis .", "label": "", "metadata": {}, "score": "57.401417"}
{"text": "PubMed Central View Article PubMed .Hamilton RG , Marcotte GV , Saini SS : Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab ( Xolair ) therapy .", "label": "", "metadata": {}, "score": "57.60521"}
{"text": "The study results supported the safety and effectiveness of omalizumab in patients with refractory CSU .About Omalizumab ( Xolair \u00ae ) .Omalizumab is a targeted therapy unique in binding to immunoglobulin E ( IgE ) .", "label": "", "metadata": {}, "score": "57.62661"}
{"text": "However , one should be cautious when comparing these two phase 1 trials as the dose progression schedules were different .A phase 2 study comparing omalizumab to placebo in participants with a similar dosing schedule is needed to truly assess the efficacy gained from the addition of omalizumab to mOIT .", "label": "", "metadata": {}, "score": "57.745888"}
{"text": "The dose of placebo consisting of sucrose , L - histidine , L - histidine hydrochloride monohydrate , and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks .", "label": "", "metadata": {}, "score": "57.8025"}
{"text": "Screening , day -35 . --prednisone / methylprednisolone and/or inhaled triamcinolone adjusted to lowest doses possible with still acceptable asthma symptoms and PEFR .--albuterol given to treatment acute symptoms .", "label": "", "metadata": {}, "score": "58.13829"}
{"text": "This parameter is also assessed in the other trials reviewed for efficacy .A summary of these trials is included below .This document contains a brief description of asthma and the product , omalizumab .", "label": "", "metadata": {}, "score": "58.216812"}
{"text": "Overall .Of a total of 53 participants screened , 25 met inclusion criteria and were enrolled in the phase 1 protocol .Detailed food allergen diagnoses are available in the online supplement ( Additional file 1 : Tables S3 ) .", "label": "", "metadata": {}, "score": "58.248672"}
{"text": "Discontinue therapy following any severe reaction .Disease - related concerns : .Concurrent drug therapy issues : .The combined use of omalizumab and corticosteroids in patients with chronic idiopathic urticaria has not been evaluated .", "label": "", "metadata": {}, "score": "58.98639"}
{"text": "Slow following SubQ injection .Distribution .V d : 78 \u00b1 32 mL / kg .Metabolism .Degradation of IgG and omalizumab : IgE complexes by reticuloendothelial system and endothelial cells in the liver .", "label": "", "metadata": {}, "score": "59.030518"}
{"text": "A protocol - defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids ( ICS ) dose for at least 3 days .", "label": "", "metadata": {}, "score": "59.049004"}
{"text": "A protocol - defined asthma exacerbation was a worsening of asthma requiring treatment with oral or intravenous corticosteroid burst and/or a doubling of the baseline inhaled corticosteroids ( ICS ) dose for at least 3 days .", "label": "", "metadata": {}, "score": "59.049004"}
{"text": "Canadian labeling : .Dosing is not dependent on serum IgE ( free or total ) level or body weight .Dosage adjustment for toxicity : .", "label": "", "metadata": {}, "score": "59.177986"}
{"text": "Flour / powder protein content was calculated according to nutritional information provided by manufacturers and confirmed through protein assays run at Stanford laboratories .Omalizumab .", "label": "", "metadata": {}, "score": "59.345848"}
{"text": "Patients were followed to week 28 .The reductions from baseline in itch severity and hive counts seen with placebo and the 75-mg omalizumab dose were maintained through this period .", "label": "", "metadata": {}, "score": "59.48275"}
{"text": "The primary efficacy endpoint ( increase in airway neutrophils ) will be assessed by comparison of the differences between sputum neutrophil influx after ozone ( adjusted for post air challenge neutrophils ) between omalizumab and placebo treated volunteers .", "label": "", "metadata": {}, "score": "59.716377"}
{"text": "Data on any potential unblinding was not provided in the submission .Protocol modifications were minor and would not have affected the assessment of efficacy .", "label": "", "metadata": {}, "score": "59.76271"}
{"text": "The trials had an adequate duration and collected clinically meaningful data .The protocols made no effort to collect information on subjects selected for high degrees of severity or those on commonly used concomitant medications in asthma .", "label": "", "metadata": {}, "score": "59.817856"}
{"text": "Total IgE level slightly increased due to omalizumab therapy .Regarding lung function , an increase in the mean peak expiratory flow ( PEF ) , along with improvement in the FEV 1 /FVC , was observed at 2 months and 4 months after initiating omalizumab therapy .", "label": "", "metadata": {}, "score": "59.81849"}
{"text": "Omalizumab is not currently approved or indicated for CSU .Regulatory submissions for omalizumab in CSU are on track for later this year .GLACIAL is the second of three pivotal Phase III studies that investigate the efficacy and safety of omalizumab in CSU .", "label": "", "metadata": {}, "score": "59.81979"}
{"text": "Replace the 18-gauge needle with a 25-gauge needle for subcutaneous injection , and expel any air , bubbles , or excess solution to obtain the 1.2 mL dose .", "label": "", "metadata": {}, "score": "59.909775"}
{"text": "Subjects were to be randomized into groups requiring either triamcinolone ( inhaled ) or prednisone ( oral ) .Trial medication was to be shipped open - label to sites , where the preparers were not to be involved in any other aspect of the trial .", "label": "", "metadata": {}, "score": "60.48217"}
{"text": "Omalizumab is an anti - IgE monoclonal antibody , which binds to free IgE in the blood and inhibits the binding between Fc .RI and IgE prevents degranulation of inflammatory mediators such as histamine and interleukins from the mast cells , thereby inhibiting the allergic response [ 2 ] .", "label": "", "metadata": {}, "score": "60.621273"}
{"text": "Multiple food allergy Safety Efficacy Omalizumab Desensitization .Electronic supplementary material .The online version of this article ( doi : 10 .1186/\u200b1710 - 1492 - 10 - 7 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "60.70164"}
{"text": "Notably , 71 ( 4.7 % ) were screened out for IgE below the treatment limit , and 21 ( 1.5 % ) were screened out for having a combination of IgE and body mass outside the dosing table limits .", "label": "", "metadata": {}, "score": "60.723633"}
{"text": "Chronic use of oral ( \u00a3 20 mg of prednisone daily or \u00a3 40 mg every other day or \u00a3 16 mg methylprednisolone daily ) or inhaled ( \u00b3 600 m g of triamcinolone ) corticosteroids at enrollment .", "label": "", "metadata": {}, "score": "60.738464"}
{"text": "Omalizumab is expected to exhibit a therapeutic effect on medical conditions associated with eosinophilic inflammation .However , since the approved indication of omalizumab is intractable asthma , very little has been reported about the efficiency of omalizumab on EOM .", "label": "", "metadata": {}, "score": "60.74328"}
{"text": "Intervention : Drug : omalizumab .Not Provided .Enrollment ICMJE .Completion Date .July 2007 .Primary Completion Date .July 2007 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "60.757053"}
{"text": "In a 323-patient , placebo - controlled trial testing three doses of the anti - IgE monoclonal antibody drug , declines from baseline in itch severity were significantly greater with the two higher doses of omalizumab compared with placebo , reported Thomas Casale , MD , of Creighton University in Omaha , Neb. .", "label": "", "metadata": {}, "score": "60.77781"}
{"text": "A full report also appeared Sunday online in the New England Journal of Medicine .Other research reported here supported the overall study findings .For example , clinicians at Yale University said in a poster presentation that they had successfully treated a 14-year - old boy with 150 mg of omalizumab , which completely abolished the patient 's persistent urticaria in 2 weeks .", "label": "", "metadata": {}, "score": "61.206657"}
{"text": "If a subject were to have taken allergy vaccination therapy ( desensitization immunotherapy ) for \u00b3 3 months of stable doses before visit 1 , he or she was to maintain this treatment unchanged throughout the trial .", "label": "", "metadata": {}, "score": "61.211166"}
{"text": "Just over twice as many subjects were screened as entered into trial 008 : 1117 vs. 525 .Notably , 53 ( 4.7 % ) were screened out for IgE below the treatment limit , and 36 ( 3.2 % ) were screened out for having a combination of IgE and body mass outside the dosing table limits .", "label": "", "metadata": {}, "score": "61.242115"}
{"text": "--The protocol defined reasons ( PEFR , FEV 1 , asthma symptoms , increase in b -agonists ) for the discontinuation or reinstitution of a taper : . \u00b7 follow - up , day 210 : . --complete physical exam , vital signs , spirometry , methacholine challenge , clinical labs , urinalysis , total and free serum IgE and product .", "label": "", "metadata": {}, "score": "61.46277"}
{"text": "The primary endpoint of the trial was defined not by these criteria , but by the doubling of prescribed inhaled corticosteroids or the institution of oral corticosteroids .", "label": "", "metadata": {}, "score": "61.548954"}
{"text": "Allergy .Intervention ICMJE .Drug : omalizumab . omalizumab as per weight and IgE .Other Name : Xolair .Study Arm ( s ) .", "label": "", "metadata": {}, "score": "61.655148"}
{"text": "In addition , the timing are closely related with the administration of omalizumab .However , this increase has not pathological significance .In conclusion , our work shows after a long follow - up the effectiveness of omalizumab with a good safety profile in a severe form of non - atopic asthma with increased levels of total IgE. It is therefore hoped that further studies identify new indicators that can give to clinicians information about asthmatic patients who can be responsive to monoclonal anti - IgE antibody even if non allergic .", "label": "", "metadata": {}, "score": "61.685787"}
{"text": "As the half - life of omalizumab is 24 days , we further hypothesized that any protective safety effect might wane over time .Participants were observed closely for the development of symptoms , including hives , worsening of eczema , or wheezing after omalizumab discontinuation ( at 8 weeks after initial dose escalation ) , and were instructed to keep a diary of food allergy symptoms throughout the study .", "label": "", "metadata": {}, "score": "61.716663"}
{"text": "Initial trials were with a liquid formulation ; subsequently , a lyophilized formulation was used .The trials reviewed in this document were performed with a lyophilized formulation ; however , the product used in trial Q0694 g , while lyophilized , differed with respect to production method , product concentration , excipients , and vial configuration .", "label": "", "metadata": {}, "score": "61.859547"}
{"text": "Research is ongoing to understand the mechanism of action of omalizumab in CSU , and to investigate its impact on the drivers of CSU5 .It may suppress histamine - induced skin reactions through its reduction of IgE and downstream effects on cellular activation mechanisms8 .", "label": "", "metadata": {}, "score": "62.024826"}
{"text": "The overall symptom score was the mean of the 16 scores for adults and 17 scores for adolescents .The actual final analysis of the primary endpoint , PEFR , and b -agonist use were performed on subjects with at least 4 weeks of post - randomization data ; other efficacy data were analyzed in all subjects .", "label": "", "metadata": {}, "score": "62.090717"}
{"text": "Table 8 shows that in trial 008 the placebo and omalizumab groups were well matched for important baseline characteristics and demographics .There were about 1\u00bd times as many females as males in the trial ( but the proportions were approximately equal in trial 009 ) .", "label": "", "metadata": {}, "score": "62.253407"}
{"text": "Safety .Rates and nature of dose reactions are depicted in Figure 2 for initial dose escalation day , dose escalations , and home dosing .", "label": "", "metadata": {}, "score": "62.256622"}
{"text": "Before omalizumab treatment , the patient had developed impaired hearing both by air and bone conduction ; however , after the second omalizumab administration , air conduction hearing improved in the low - frequency range in both ears .", "label": "", "metadata": {}, "score": "62.25743"}
{"text": "In this phase 1 safety study , we have shown that participants allergic to multiple foods were safely and rapidly desensitized to up to five food allergens simultaneously , using a rush OIT protocol with concomitant treatment with omalizumab .", "label": "", "metadata": {}, "score": "62.52164"}
{"text": "The exclusion criteria were extensive .They narrowed the population to those effectively treated with a narrow spectrum of medications , which is a concern for both the safety and efficacy evaluation .", "label": "", "metadata": {}, "score": "62.538036"}
{"text": "Geriatric subjects were excluded .Discontinuations from the trial were slightly more common among placebo subjects ( about 15 % vs. 10 % ( omalizumab lower dose ) or 7 % ( omalizumab higher dose ) ) .", "label": "", "metadata": {}, "score": "62.552643"}
{"text": "10.1111/j.1398 - 9995.2004.00772.x .View Article PubMed .Rodrigo GJ , Neffen H , Castro - Rodriguez JA : Efficacy and safety of subcutaneous omalizumab versus placebo ad add on therapy to corticosteroids for children and adults with asthma : a systematic review .", "label": "", "metadata": {}, "score": "62.639576"}
{"text": "Table 7 .Dosing table for trials 008 and 009( milligrams / dose ) .Comments .This dosing goal of a minimum 4-weekly dose was replicated in every important trial of efficacy .", "label": "", "metadata": {}, "score": "62.723038"}
{"text": "In the study , the incidence and severity of adverse events ( AEs ) was similar between omalizumab and placebo recipients , with no new safety issues identified1 .", "label": "", "metadata": {}, "score": "62.736206"}
{"text": "Table 4 .Trial Q0694 g : Inhaled corticosteroid reductions ( subjects on inhaled corticosteroid only ) .P - values compare the omalizumab groups to placebo using the Wilcoxon rank - sum test for continuous . endpoints and Pearson c 2 test for binary endpoints .", "label": "", "metadata": {}, "score": "62.973343"}
{"text": "About the GLACIAL Study .GLACIAL was a 40-week , global , multi - center , randomized double - blind study that evaluated the safety and efficacy of omalizumab compared to placebo .", "label": "", "metadata": {}, "score": "63.00161"}
{"text": "Novartis has announced late - breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria ( CSU)1 , a chronic and debilitating form of hives with limited approved treatment options2 - 4 .", "label": "", "metadata": {}, "score": "63.088463"}
{"text": "PubMed .Lieberman JA , Chehade M : Use of omalizumab in the treatment of food allergy and anaphylaxis .Curr Allergy Asthma Rep. 2013 , 13 ( 1 ) : 78 - 84 .", "label": "", "metadata": {}, "score": "63.189526"}
{"text": "Therefore , IgE may have a key role in the inflammatory cascade ( even in the absence of a proved aeroallergen ) contributing to bronchial hyper reactivity and remodeling in asthma .", "label": "", "metadata": {}, "score": "63.199013"}
{"text": "Although 13 participants ( 52 % ) experienced some symptom on their initial dose escalation day , 19 ( 76 % ) were able to reach the full 1250 mg of food protein total .", "label": "", "metadata": {}, "score": "63.282604"}
{"text": "However , the only use of epinephrine occurred shortly after the participant had reached the maintenance phase , thus vigilance should not be relaxed at any point .", "label": "", "metadata": {}, "score": "63.459465"}
{"text": "Oral corticosteroids are known to have systemic side effects such as suppression of growth in children , cataract formation , osteoporosis , and disturbance of glycemic control .", "label": "", "metadata": {}, "score": "63.494583"}
{"text": "Seven ( 2.8 % ) patients experienced SAEs in the omalizumab group , compared to three ( 3.6 % ) in the placebo group1 .No deaths were reported during this study1 .", "label": "", "metadata": {}, "score": "63.508774"}
{"text": "Since all subjects received at least one injection , this was equivalent to an intent - to - treat population .Table 14 shows exacerbations as determined in trial 008 using the protocol - defined technique of imputation .", "label": "", "metadata": {}, "score": "63.645493"}
{"text": "The trial intended to study asthmatics selected for skin test reactivity and exposure to an allergen or allergens .The subject population was allowed to take moderate amounts of oral corticosteroids , which would tend to allow more severe asthmatics than studied in the pivotal trials .", "label": "", "metadata": {}, "score": "63.70831"}
{"text": "Because of the risk of anaphylaxis , observe patients closely for an appropriate period of time after omalizumab administration .Health care providers administering omalizumab should be prepared to manage anaphylaxis that can be life - threatening .", "label": "", "metadata": {}, "score": "63.77957"}
{"text": "Since the product was to be targeted to children as well as to adults , a body weight correction was added .Comment .The a priori relevance of serum free IgE suppression is unclear , since the release of histamine and other mediators from IgE - receptor - bearing cells is more dependent upon bound IgE than on free IgE , and the relation of bound to free IgE is complex .", "label": "", "metadata": {}, "score": "63.89616"}
{"text": "Table 9 shows that in trial 009 the placebo and omalizumab groups were also well matched for important baseline characteristics and demographics .In contrast to trial 008 , the proportions of each gender enrolled was nearly matched .", "label": "", "metadata": {}, "score": "63.968056"}
{"text": "Inhaled corticosteroids are considered much safer , due to much less systemic exposure .Troleandomycin , methotrexate , cyclosporine , and other immunomodulators have been tried in cases of glucocorticoid - resistant asthma , or in severe cases in which corticosteroids may be contraindicated .", "label": "", "metadata": {}, "score": "64.027054"}
{"text": "Pharmacology .Asthma : Omalizumab is an IgG monoclonal antibody ( recombinant DNA derived ) which inhibits IgE binding to the high - affinity IgE receptor on mast cells and basophils .", "label": "", "metadata": {}, "score": "64.052956"}
{"text": "Because improvement was observed at 4 months after the start of omalizumab therapy , PSL dose was reduced .However , after 1 year , exacerbation of asthma symptoms with concurrent infection was observed , with simultaneous PEF decrease .", "label": "", "metadata": {}, "score": "64.08711"}
{"text": "Li noted that more than half of the patients in the trial 's 300-mg group still had some residual symptoms .Since that dose is much lower than the maximum recommended for asthma patients , he suggested that it might be worthwhile to try higher doses .", "label": "", "metadata": {}, "score": "64.09971"}
{"text": "Given that reactions are expected to occur with OIT , training for the use of and indication for auto - injectable epinephrine was given to all participants and families / guardians at screening , on the initial dose escalation day and every three months during OIT .", "label": "", "metadata": {}, "score": "64.118744"}
{"text": "Also , a study by Berger and cohautors showed that the in vitro incubation with omalizumab of bronchial tissue from asthmatic patients , inhibits specific and aspecific bronchial hyper - responsiveness .", "label": "", "metadata": {}, "score": "64.20282"}
{"text": "View Article .Respir Med .10.1016/j.rmed.2009.06.014 .View Article PubMed .Van den Berge M , Pauw RG , de Monchy JGR , van Minnen CA , Postma DS , Kerstjens HA : Beneficial effects of treatment with anti - IgE antibodies ( omalizumab ) in a patient with severe asthma and negative skin - prick test results .", "label": "", "metadata": {}, "score": "64.22954"}
{"text": "In December 2009 , omalizumab therapy was started for refractory asthma .After 2 months of omalizumab treatment , not only asthma , but also hearing loss improved .", "label": "", "metadata": {}, "score": "64.27406"}
{"text": "Itch severity was rated weekly by patients on a 21-point scale .The mean at baseline was about 14 .Significant dose - dependent advantages for omalizumab over placebo were also seen for several secondary endpoints , including weekly urticaria counts , Dermatology Life Quality Index scores , and the proportion of patients with scores of 6 or less on a 42-point index of urticaria activity ( UAS7 ) .", "label": "", "metadata": {}, "score": "64.537384"}
{"text": "Changes in PEFR were small in placebo and omalizumab groups .At baseline all groups were at about 380 l / min ; at week 20 the increases , in liters / min in the placebo , lower , and higher dose treatment groups were about 10 , 21 , and 30 l / min , respectively .", "label": "", "metadata": {}, "score": "64.61103"}
{"text": "Serum free IgE levels and the number of high - affinity IgE receptors are decreased .Long - term treatment in patients with allergic asthma showed a decrease in asthma exacerbations and corticosteroid usage .", "label": "", "metadata": {}, "score": "64.72896"}
{"text": "Serum was assayed for antibodies to either Fc or F(Ab ' ) 2 portion of omalizumab .Genentech reports that no antibody development occurred .In any event , lack of development of antibodies to the product after its intravenous administration may not be relevant to its immunogenicity after subcutaneous administration ( the intended route ) .", "label": "", "metadata": {}, "score": "64.74333"}
{"text": "Figure 3 .Treatment of asthma exacerbations during stable steroid phase .Comment .The protocol guidelines include the step of intravenous corticosteroids for severe episodes , while the published guidelines do not mention this step explicitly , instead recommending proceeding to an emergency department .", "label": "", "metadata": {}, "score": "64.91275"}
{"text": "Either a minimum of 0.016 mg / kg / IgE ( IU / mL ) every 4 weeks or 0.008 mg / kg / IgE ( IU / mL ) every 2 weeks ( based on dosing table ) .", "label": "", "metadata": {}, "score": "64.98597"}
{"text": "Either a minimum of 0.016 mg / kg / IgE ( IU / mL ) every 4 weeks or 0.008 mg / kg / IgE ( IU / mL ) every 2 weeks ( based on dosing table ) .", "label": "", "metadata": {}, "score": "64.98597"}
{"text": "Participants with multiple food allergies received OIT for up to 5 allergens simultaneously with omalizumab ( rush mOIT ) .Omalizumab was administered for 8 weeks prior to and 8 weeks following the initiation of a rush mOIT schedule .", "label": "", "metadata": {}, "score": "65.01864"}
{"text": "There was one severe reaction .Participants reached their maintenance dose of 4,000 mg protein per allergen at a median of 18 weeks .Conclusion .", "label": "", "metadata": {}, "score": "65.02447"}
{"text": "2013 , EPub May 17 2013 .Nadeau KC , Kohli A , Iyengar S , DeKruyff RH , Umetsu DT : Oral immunotherapy and anti - IgE antibody - adjunctive treatment for food allergy .", "label": "", "metadata": {}, "score": "65.081604"}
{"text": "In our patient the GETE rating at 3 years was excellent , confirming the effectiveness of omalizumab .Health - related quality of life ( HRQoL ) was assessed by means of the AQLQ score [ 8 ] .", "label": "", "metadata": {}, "score": "65.08726"}
{"text": "Subsequently , IgE receptors ( Fc\u03b5RI ) on cells down - regulate .The mechanism by which these effects of omalizumab result in an improvement of chronic idiopathic urticaria symptoms is unknown .", "label": "", "metadata": {}, "score": "65.09855"}
{"text": "MLA Novartis . \"Omalizumab Significantly Improves Itch In Patients With Severe Form Of Chronic Skin Disease CSU , New Study .\" Medical News Today .", "label": "", "metadata": {}, "score": "65.20271"}
{"text": "Omalizumab is a recombinant Chinese Hamster Ovary cell - derived humanized IgG1 k monoclonal antibody .It binds to IgE and inhibits the binding of IgE to Fc e RI , the high affinity receptor for IgE on mast cells and basophils .", "label": "", "metadata": {}, "score": "65.22113"}
{"text": "Individual doses were provided containing all of the participant 's allergens .Participants were instructed to ingest their dose after a full meal at approximately the same time each day .", "label": "", "metadata": {}, "score": "65.45566"}
{"text": "Subjects with large or prolonged corticosteroid requirements were to be excluded .The asthma symptom score used for inclusion was also used as the primary endpoint data .", "label": "", "metadata": {}, "score": "65.46619"}
{"text": "In addition , production method changes between the material used in Q0694 g and trials 008 - 010 lessen the relevance of these data to those developed in the latter trials .", "label": "", "metadata": {}, "score": "65.68643"}
{"text": "All participants performed spirometry , as appropriate per age , and had continuous pulse - oximetry and vital sign monitoring , every 15 minutes prior to and following increasing doses of placebo or allergenic food protein .", "label": "", "metadata": {}, "score": "65.736435"}
{"text": "It is acceptable if there are a few small bubbles or foam around edge of vial .Resulting solution is 150 mg per 1.2 mL. Invert the vial for 15 seconds so the solution drains toward the stopper .", "label": "", "metadata": {}, "score": "65.99306"}
{"text": "However , because the asthma was poorly controlled , she had been regularly taking inhaled corticosteroid ( ICS ) , LABA , antileukotriene agents , and oral steroids ( prednisolone ( PSL ) , 10 - 15 mg / day ) .", "label": "", "metadata": {}, "score": "66.027176"}
{"text": "Use : Labeled Indications .Asthma : Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids .", "label": "", "metadata": {}, "score": "66.031265"}
{"text": "Intertreatment differences in the changes in symptom scores were small ; equivocal differences were seen in different measures of pulmonary function .Intravenous omalizumab treatment was associated with lower asthma exacerbations rates .", "label": "", "metadata": {}, "score": "66.05234"}
{"text": "Oral immunotherapy regimens were customized to the participant 's food allergies .This has led to some diversity when comparing the composition of specific food allergies between subjects .", "label": "", "metadata": {}, "score": "66.05822"}
{"text": "Up to 40 % of CSU patients fail on antihistamines , even those taking up to four times the approved dose5 .Antihistamines , at the approved dose , are currently the only licensed treatment for CSU .", "label": "", "metadata": {}, "score": "66.06123"}
{"text": "Results .Twenty - five ( 25 ) participants were enrolled in the protocol ( median age 7 years ) .For each included food , participants had failed an initial double - blind placebo - controlled food challenge at a protein dose of 100 mg or less .", "label": "", "metadata": {}, "score": "66.113625"}
{"text": "It would more closely resemble conditions of real use , but it would come after a period of use of the investigational agent and a steroid reduction phase immediately preceding it .", "label": "", "metadata": {}, "score": "66.13208"}
{"text": "PubMed .Schneider LC , Rachid R , Lebovidge J , Blood E , Mittal M , Umetsu DT : A pilot study of omalizumab to facilitate rapid oral desensitization in high - risk peanut - allergic patients .", "label": "", "metadata": {}, "score": "66.1877"}
{"text": "A high - resolution chest CT showed no signs of parenchymal lung disease .Blood tests showed peripheral eosinophilia ( 8 % ) and total IgE were 272.6 KIU / L without specific IgE to inhalant or food allergens testing with ImmunoCap ( Phadia , Sweden ) .", "label": "", "metadata": {}, "score": "66.2007"}
{"text": "Case Report .In May 2006 a Caucasian 52-year - old man came to our observation because of severe persistent asthma not controlled despite an extensive therapy ( formoterol 18 mcg / day ; budesonide 640 mcg / day ; tiotropium bromide 18 mcg / day ) , oral steroids ( prednisone 25 mg / day ) .", "label": "", "metadata": {}, "score": "66.24469"}
{"text": "Written informed consent was obtained from the patient for publication of this case report .Authors ' information .The Centre the authors belong to participated in the last International Clinical Trial on omalizumab ( CIGE025A2425 ) as National Coordinating Centre for Italy .", "label": "", "metadata": {}, "score": "66.333244"}
{"text": "In the EU it is approved for the treatment of severe allergic asthma in children ( aged six and above ) , adolescents , and adults .", "label": "", "metadata": {}, "score": "66.34515"}
{"text": "For the sake of brevity this briefing document does not mention various safety - related determinations and procedures that were done .Exacerbations of asthma were the cornerstone of the efficacy evaluation .", "label": "", "metadata": {}, "score": "66.65393"}
{"text": "Reductions in corticosteroid dosing too close to the end of the steroid reduction phase were infrequent and approximately equal in occurrence in the two treatment arms . \u00b7", "label": "", "metadata": {}, "score": "66.873"}
{"text": "--recording of adverse events and symptom scores , albuterol use , and PEFR .\u00b7 Day 0 : . --asthma evaluations and first infusion . \u00b7", "label": "", "metadata": {}, "score": "66.90741"}
{"text": "or medium - acting antihistamines were allowed for the treatment of allergic rhinitis .Subjects were not to start desensitization immunotherapy for allergies .Comment .", "label": "", "metadata": {}, "score": "66.99095"}
{"text": "However , due to its importance in relation to the primary endpoint of the pivotal trials , these data will be summarized here .The data suggest that the treatment reduced the number of asthma exacerbations reported as adverse events , to the same level regardless of dose .", "label": "", "metadata": {}, "score": "67.12248"}
{"text": "It was amended 3 times , all after trial initiation on April 5 , 1996 .None of the changes would have been expected to alter the judgment of the treatment effect significantly .", "label": "", "metadata": {}, "score": "67.12779"}
{"text": "Omalizumab inactivates IgE , a protein our own immune systems make as part of allergic reactions .The purpose of this study is to test the hypothesis that omalizumab , by blocking this aspect of allergic reactions , will decrease the number of inflammatory cells in the airway after ozone challenge .", "label": "", "metadata": {}, "score": "67.135735"}
{"text": "Treatments were to be shipped to sites open - label .Each site was responsible for reconstitution of treatments prior to administration and for ensuring that personnel responsible for reconstitution and administration were not be involved in subject evaluations .", "label": "", "metadata": {}, "score": "67.28516"}
{"text": "The family did not report any obvious triggers such as exercise or viral infection .Dose progression .As up - dosing was dependent on tolerance to the current dose , dose progression was treated as a marker of tolerability .", "label": "", "metadata": {}, "score": "67.33038"}
{"text": "Injections may take 5 to 10 seconds to administer ( solution is slightly viscous ) .Administer only under direct medical supervision and observe patient for a minimum of 2 hours following administration of any dose given .", "label": "", "metadata": {}, "score": "67.34681"}
{"text": "10.1016/j.jaci.2005.09.036 .PubMed .Nadeau KC , Schneider LC , Hoyte L , Borras I , Umetsu DT : Rapid oral desensitization in combination with omalizumab therapy in patients with cow 's milk allergy .", "label": "", "metadata": {}, "score": "67.507774"}
{"text": "The Global Initiative for Asthma suggests use be considered as adjunctive therapy in patients with moderate or severe allergic asthma that is uncontrolled with a combination of a medium- to high - dose inhaled corticosteroid and a long - acting beta 2 -agonist ( GINA 2015 ) .", "label": "", "metadata": {}, "score": "67.65587"}
{"text": "Subjects on the every 2-week schedule required additional clinic visits for injections .They received the following at the intervening visits : .Comment .", "label": "", "metadata": {}, "score": "67.71786"}
{"text": "They were instructed not to miss their daily dose .Participants and their families were given instructions on how to monitor for reactions at home and record any symptoms in their dosing diary .", "label": "", "metadata": {}, "score": "67.75984"}
{"text": "Over the study period , there were 3 withdrawals because of non - compliance with study medication .Overall , a total of 227 hospital - based dose escalation doses and 7,530 home doses were given ( Table 4 ) .", "label": "", "metadata": {}, "score": "67.7919"}
{"text": "If home daily protein flour / powder doses had been well tolerated , the dose was increased in the hospital setting according to a predetermined scale as outlined in Table 2 .", "label": "", "metadata": {}, "score": "67.796616"}
{"text": "View Article PubMed .Hayashi N , Tsukamoto Y , Sallas WM , Lowe PJ : A mechanism - based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab .", "label": "", "metadata": {}, "score": "67.8564"}
{"text": "Week 5 : Visit for injection of omalizumab vs. placebo ( CEMALB nurse ) ; urine pregnancy test if applicable .Week 7 : Visit for injection of omalizumab vs. placebo ; urine pregnancy test if applicable .", "label": "", "metadata": {}, "score": "67.87381"}
{"text": "MW and AB performed work on food flours / powders .RH performed serological analyses .PB , and KN drafted the manuscript .All authors revised the manuscript and approved the final version .", "label": "", "metadata": {}, "score": "67.87488"}
{"text": "A substantial proportion of subjects were screened out of both of these trials due to serum IgE levels or FEV 1 higher than the limit for the trials ; a smaller , and notable numbers were screened out due to IgE levels lower than the protocol limit .", "label": "", "metadata": {}, "score": "67.91724"}
{"text": "LateBreakingPoster .25 June 2013 , 12:00 p.m. .Casale T , Maurer M , Hsieh HJ , et al .Efficacy and safety of omalizumab in chronic idiopathic / spontaneous urticaria : results from a phase III , randomized , double - blind , placebo - controlled trial ( ASTERIA II ) .", "label": "", "metadata": {}, "score": "67.93172"}
{"text": "Patients were randomized to omalizumab 300 mg or placebo ( 3:1 ) , given subcutaneously every four weeks for a total period of 24 weeks1 .", "label": "", "metadata": {}, "score": "68.07272"}
{"text": "If the new dose was tolerated , it subsequently became their daily dose for the following two weeks ; otherwise they continued on their previous dose .", "label": "", "metadata": {}, "score": "68.16947"}
{"text": "There is no approved treatment for CSU that is broadly effective in more than 50 % patients who are not responding to approved doses of antihistamines , the mainstay of current symptomatic therapy6 .", "label": "", "metadata": {}, "score": "68.22419"}
{"text": "The patient was followed until July 2010 and in that range he had only two mild relapses and no hospitalization .The AQLQ score arrived at 5.43 confirming a marked improvement in the quality of life ; spirometry showed a discrete increase ( FEV1 1.70 l ; 53 % of predicted ) compared to baseline ( FEV1 +15 % ) .", "label": "", "metadata": {}, "score": "68.23274"}
{"text": "Placebo Comparator : Placebo .Placebo administered in this study was either a minimum of 0.008 mg / kg / IgE [ IU / mL ] every 2 weeks or a minimum of 0.016 mg / kg / IgE [ IU / mL ] every 4 weeks .", "label": "", "metadata": {}, "score": "68.244125"}
{"text": "units / mL:30 - 60 kg : 375 mg every 2 weeks .Subjects for whom the IgE level and weight indicate that no dose will be given will be excluded from the study .", "label": "", "metadata": {}, "score": "68.24854"}
{"text": "Use of b -adrenergic antagonist medications ( e.g. , propranolol ) .Smoking within 2 years of Visit 1 or history of smoking \u00b3 10 pack years .", "label": "", "metadata": {}, "score": "68.362976"}
{"text": "Interim analysis .There was to be no interim analysis .The efficacy analysis was to be initiated at the completion of the steroid reduction phase , prior to completion of the extension period .", "label": "", "metadata": {}, "score": "68.42311"}
{"text": "Amount of maintenance dose depends on number of allergens dosed ( 4000 mg per allergen ) .All participants were admitted to the CTFU ( clinical trial food unit ) and vital signs ( heart rate , respiratory rate , temperature , blood pressure and pulse oximetry ) were monitored every 15 minutes .", "label": "", "metadata": {}, "score": "68.560524"}
{"text": "Time distribution of home dosing reactions for the first year of rush mOIT .Throughout the trial , there were no serious adverse events .One severe reaction occurred shortly after reaching maintenance phase ( 16,000 mg ) in a participant desensitized to peanut , almond , milk and egg .", "label": "", "metadata": {}, "score": "68.68257"}
{"text": "FEV 1 criteria violations in trial 009 were unbalanced , but relatively infrequent , and occurred in opposite directions in a balanced way . \u00b7Genentech expressed dosing violations for mean dose as numbers of subjects with mean dose less than 0.008 mg / kg / IU / ml every 2 weeks .", "label": "", "metadata": {}, "score": "68.81096"}
{"text": "However , one major limitation to the clinical application of current protocols is their use in participants with more than one food allergy , which would require multiple sequential rounds of immunotherapy over many years .", "label": "", "metadata": {}, "score": "68.83474"}
{"text": "In order to standardize corticosteroid treatment , at visit 2 all subjects were switched to inhaler treatment twice a day with BDP , 84 m g / puff , at a total dose comparable to the corticosteroid the subject had been on prior to the trial .", "label": "", "metadata": {}, "score": "68.871574"}
{"text": "History of acute infectious sinusitis or respiratory tract infection within 1 month prior to Visit 1 .Aspirin or other nonsteroidal anti - inflammatory drug - related asthma .", "label": "", "metadata": {}, "score": "68.88319"}
{"text": "PubMed .Sabato V , Faber M , Van Gasse A , Hagendorens MM , Leysen J , Bridts CH : State of the art and perspectives in food allergy ( part II ) : therapy .", "label": "", "metadata": {}, "score": "68.919815"}
{"text": "Clinical reactivity was based on Bock 's criteria ( grade 1 or above ) [ 53 ] .The DBPCFC procedure used was described in a previous publication [ 36 ] .", "label": "", "metadata": {}, "score": "68.92228"}
{"text": "Study medications .Food flours / powders .A Chemistry and Manufacturing Control ( CMC ) section for each food allergen powder / flour included assessments for stability , identity , relative sterility , and purity of each of the food powders / flours .", "label": "", "metadata": {}, "score": "68.96376"}
{"text": "10.1016/j.jaci.2007.10.029 .PubMed .Meglio P , Bartone E , Plantamura M , Arabito E , Giampietro PG : A protocol for oral desensitization in children with IgE - mediated cow 's milk allergy .", "label": "", "metadata": {}, "score": "69.06419"}
{"text": "PubMed .Patil SP , Wang J , Song Y , Noone S , Yang N , Wallenstein S : Clinical safety of food allergy herbal formula-2 ( FAHF-2 ) and inhibitory effect on basophils from patients with Food allergy : extended phase I study .", "label": "", "metadata": {}, "score": "69.145004"}
{"text": "Mild mite sensitive asthmatics on placebo .Week 1 : Visit for injection of omalizumab vs. placebo ( injections carried out by CEMALB nurse ; MD immediately available in facility ) ( see below for dosing of omalizumab ) ; phlebotomy for baseline CBC with platelets ; urine pregnancy test if applicable .", "label": "", "metadata": {}, "score": "69.16989"}
{"text": "They were to have symptomatic asthma while on a stable dose of corticosteroid and rescue bronchodilators .Inclusion criteria .Male and female , aged 12 - 75 years , willing to sign informed consent .", "label": "", "metadata": {}, "score": "69.301476"}
{"text": "Test Interactions .Total IgE levels are elevated for up to 1 year following treatment .Total serum IgE may be retested after interruption of therapy for 1 year or more .", "label": "", "metadata": {}, "score": "69.362946"}
{"text": "For both trials , run - in period duration violations were relatively frequent but were balanced between arms . \u00b7 Rescue medication violations prior to spirometry were not well balanced and might have affected FEV 1 , a secondary endpoint , biasing against the product . \u00b7", "label": "", "metadata": {}, "score": "69.48164"}
{"text": "Planned enrollment was 550 subjects each .Table 6 is a schematic of the trials .Following this were 5 months of double - blind extension , during which subjects were to remain on their assigned treatment , but concomitant medications and the dose of prescribed corticosteroid were to be liberalized .", "label": "", "metadata": {}, "score": "69.58537"}
{"text": "--For subjects on inhaled triamcinolone at doses \u00b3 600 m g / d , every-2-week tapering .--For subjects on ( ingested ) prednisone at \u00a3 20 mg / d or 40 mg QOD , or ( ingested ) methylprednisolone , \u00a3 16 mg / d , tapering to 0 by week 8 of the phase .", "label": "", "metadata": {}, "score": "69.74939"}
{"text": "This study was designed as a proof of concept , open - label phase 1 study , with safety measurements as the primary endpoint .The rate of reactions observed in the rush mOIT group was similar to a group with the same eligibility and demographics undergoing mOIT in a previous study without omalizumab , despite the more rapid desensitization schedule [ 36 ] .", "label": "", "metadata": {}, "score": "69.84941"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00096954 A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti - IgE Monoclonal Antibody Omalizumab .", "label": "", "metadata": {}, "score": "69.85771"}
{"text": "Management : This is specific to the Adasuve brand of loxapine , which is an inhaled formulation .This does not apply to non - inhaled formulations of loxapine .", "label": "", "metadata": {}, "score": "69.923874"}
{"text": "According to the NHLBI Guidelines , based on FEV 1 alone these subjects would be expected to have moderate persistent or severe persistent asthma .However , the protocol did not limit the selection of subjects to those with a history of moderate to severe symptomalogy , those with a history of frequent medical care , or those with need for additional concomitant medications beyond medium doses of corticosteroids .", "label": "", "metadata": {}, "score": "70.00368"}
{"text": "Official Title ICMJE .Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab .Brief Summary .Ozone can cause acute airway inflammation in both asthmatics and normal volunteers .", "label": "", "metadata": {}, "score": "70.02252"}
{"text": "Table 12 .IgE / weight out of dosing table range .Table 13 .Trial 009: Most common protocol violations during core and extension periods ( proportion of subjects affected per group ) .", "label": "", "metadata": {}, "score": "70.074356"}
{"text": "Daily requirement for albuterol due to asthma symptoms ( cough , wheeze , chest tightness ) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma .", "label": "", "metadata": {}, "score": "70.28841"}
{"text": "Monitoring Parameters .Anaphylactic / hypersensitivity reactions , baseline serum total IgE ; FEV 1 , peak flow , and/or other pulmonary function tests ; monitor for signs of infection .", "label": "", "metadata": {}, "score": "70.338455"}
{"text": "Chronic daily use of oral corticosteroids for more than 12 months .Receipt of escalating doses of immunotherapy .Greater than 150 % of ideal body weight for height ( adults ) or weight ( adolescents ) .", "label": "", "metadata": {}, "score": "70.339294"}
{"text": "Aggregation of the underlying Fc e RI receptors triggers the cells to release histamine and other mediators of the allergic response .Omalizumab is meant to reduce the pool of IgE available to interact with Fc e RI and thereby reduce the allergic response .", "label": "", "metadata": {}, "score": "70.383354"}
{"text": "Subjects were to remain on the dose of BDP established during the run - in period .If an exacerbation were to occur , after treatment the subject was to return to this baseline dose .", "label": "", "metadata": {}, "score": "70.394875"}
{"text": "Conclusions .Omalizumab improved the asthma symptoms and hearing in a patient with severe persistent asthma with interactive EOM and progressive hearing loss .In patients with severe asthma , treatment of the complication symptoms is indispensable .", "label": "", "metadata": {}, "score": "70.46262"}
{"text": "The median time to reach maintenance dose ( 4000 mg per allergen ) was 18 weeks [ 7 - 36 weeks ] with all participants able to reach this dose by 9 months .", "label": "", "metadata": {}, "score": "70.538994"}
{"text": "Omalizumab ( Placebo in Q2788 g ) .Omalizumab ( Omalizumab in Q2788 g ) .Number of Participants Analyzed [ units : participants ] .", "label": "", "metadata": {}, "score": "70.565735"}
{"text": "PubMed Central PubMed .Yu GP , Tuano KS , Hamilton RG , Nadeau KC : Omalizumab in peanut - allergic patients reduces free IgE anti - peanut and skin prick test to peanut .", "label": "", "metadata": {}, "score": "70.6352"}
{"text": "PubMed .Berger P , Scotto - Gomez E , Molimard M , Marthan R , Le Gros V , Tunon - de - Lara JM : Omalizumab decreases non - specific airway hyperresponsiveness .", "label": "", "metadata": {}, "score": "70.69739"}
{"text": "Able to use the Mini - Wright peak flow meter for the measurement of peak flow , and a metered - dose inhaler ( MDI ) for administration of albuterol rescue medication . \u00b7 nocturnal symptoms . \u00b7", "label": "", "metadata": {}, "score": "70.78617"}
{"text": "Use of systemic steroid therapy within the preceding 12 months .Use of inhaled steroids , cromolyn or leukotriene inhibitors ( Montelukast or zafirkulast ) initiated within the past month ( except for use of cromolyn exclusively prior to exercise ) .", "label": "", "metadata": {}, "score": "71.03494"}
{"text": "The AQLQ was found to be valid , reproducible and responsive to change over time and a change in questionnaire score of 0.5 or more points has been determined to be the minimal clinically important difference [ 8 ] .", "label": "", "metadata": {}, "score": "71.14882"}
{"text": "Serological analyses were performed for peanut to allow for consistent comparisons between participants , as this was the most frequent allergen .The serologic changes after 52 weeks of therapy were identical to those previously reported in subjects undergoing non - rush OIT ( without omalizumab ) [ 36 , 58 ] .", "label": "", "metadata": {}, "score": "71.24614"}
{"text": "Trial Q0630 g studied 20 subjects , trial Q0634 g studied 19 , and Q0694 g studied 317 subjects .Trial Q0694 g was the first asthma trial to use a lyophilized formulation but was consistent with previous trials in that it involved the intravenous route .", "label": "", "metadata": {}, "score": "71.36223"}
{"text": "For example , a patient with severe persistent asthma with frequent hospitalizations on treatment or requiring large doses of oral corticosteroids would be considered more refractory than another patient with severe persistent asthma who had not been hospitalized or who does not require systemic corticosteroids .", "label": "", "metadata": {}, "score": "71.40646"}
{"text": "--infusion every 2 weeks ( last infusion on day 133 ) . --asthma and routine evaluations . --total and free serum IgE and product at days 91 , 133 , and 140 .", "label": "", "metadata": {}, "score": "71.53032"}
{"text": "For subjects with a FEV 1 of \u00b3 70 % predicted , a positive response to inhalation of methacholine ( PC 20 FEV 1 [ Methacholine ] equal to or less than 8 mg / ml ) .", "label": "", "metadata": {}, "score": "71.59991"}
{"text": "Week 11 : Visit for injection of omalizumab vs. placebo , phlebotomy for CBC and platelets ; urine pregnancy test if applicable .Randomization of chamber exposure order ( for each cohort ) ( SC ) : .", "label": "", "metadata": {}, "score": "71.788246"}
{"text": "Change from baseline in FEV 1 .There were no clinically important or statistically significant differences during the trial between either treatment group and placebo in change in FEV 1 from baseline to the end of the stable steroid or steroid reduction phase . \u00b7", "label": "", "metadata": {}, "score": "71.79626"}
{"text": "In addition to the safety data , this phase 1 study of rush mOIT provides initial preliminary evidence of increased dose tolerability .The median time at which participants on rush mOIT reached their maintenance dose ( 4000 mg per allergen ) was 67 weeks earlier than that reported in a previous report on mOIT without omalizumab [ 36 ] .", "label": "", "metadata": {}, "score": "71.89556"}
{"text": "A definitive diagnosis is established when the aforementioned condition is observed in conjunction with bronchial asthma , nasal polyps , history of dural incision , or resistance to antimicrobial agents ( Table 3 ) [ 4 ] .", "label": "", "metadata": {}, "score": "72.21246"}
{"text": "During this period , steroid reduction was to be attempted , with biweekly clinic visits for all subjects and telephone calls .Reduction rules were : . \u00b7", "label": "", "metadata": {}, "score": "72.45199"}
{"text": "10.1016/j.jaci.2012.05.039 .e2 PubMed Central PubMed .MacGlashan DW , Savage JH , Wood RA , Saini SS : Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors .", "label": "", "metadata": {}, "score": "72.47207"}
{"text": "10.1016/j.jaci.2008.09.030 .PubMed Central PubMed .Pajno GB , Caminiti L , Ruggeri P , De Luca R , Vita D , La Rosa M : Oral immunotherapy for cow 's milk allergy with a weekly up - dosing regimen : a randomized single - blind controlled study .", "label": "", "metadata": {}, "score": "72.52388"}
{"text": "Are pregnant or lactating .Have a known hypersensitivity to any ingredients of Xolair , including excipients ( sucrose , histidine , polysorbate 20 ) .", "label": "", "metadata": {}, "score": "72.55974"}
{"text": "Immediately following the steroid reduction phase , subjects could enter a double - blind extension .In addition there was to be no restriction on the use of concomitant medications .", "label": "", "metadata": {}, "score": "72.72606"}
{"text": "The trial population was primarily Caucasian and composed of slightly more females than males ; 80 - 85 % of the trial were adults .Proportionately more subjects had a history of hospitalization than in the critical efficacy trials , and this trial enrolled subjects on oral corticosteroids , unlike the critical efficacy trials .", "label": "", "metadata": {}, "score": "72.770744"}
{"text": "10.1136/adc.2009.172460 .PubMed .Staden U , Rolinck - Werninghaus C , Brewe F , Wahn U , Niggemann B , Beyer K : Specific oral tolerance induction in food allergy in children : efficacy and clinical patterns of reaction .", "label": "", "metadata": {}, "score": "72.81088"}
{"text": "Spirometry was used to assess FEV1 .All spirometry measurements were performed in accordance with the American Thoracic Society ( ATS ) guidelines .Omalizumab ( Xolair ) administered in this study was either a minimum of 0.008 mg / kg / IgE [ IU / mL ] every 2 weeks or a minimum of 0.016 mg / kg / IgE [ IU / mL ] every 4 weeks .", "label": "", "metadata": {}, "score": "72.9332"}
{"text": "10.1034/j.1399 -3003.2000.16d07.x .View Article PubMed .Holgate ST , Djukanovic R , Casale T , Bousquet J : Anti - immunoglobulin E treatment with omalizumab in allergic diseases : an update on anti - inflammatory activity and clinical efficacy .", "label": "", "metadata": {}, "score": "73.08765"}
{"text": "This review reflects the final amended version of the protocol , with other changes as noted ( see section of review on protocol modifications ) .", "label": "", "metadata": {}, "score": "73.227325"}
{"text": "Physiological variables of greatest interest were FEV 1 and peak flow .The determination of efficacy during the core period was appropriately separated from the evaluation of asthma exacerbations in the double - blind extension period of the trial , as concomitant medications and corticosteroid use were to be different in the two periods ( liberalized in the extension ) .", "label": "", "metadata": {}, "score": "73.23636"}
{"text": "Onset of symptoms generally occurred 1 to 5 days following the first or subsequent doses .Discontinue therapy in any patient reporting this constellation of signs / symptoms .", "label": "", "metadata": {}, "score": "73.364006"}
{"text": "No statistical analysis provided for Food - allergic Reactions As Assessed by the Ewan Scale This was a multicenter , parallel - group , double - blind , randomized , placebo - controlled study that enrolled 333 subjects .", "label": "", "metadata": {}, "score": "73.575745"}
{"text": "10.1378/chest.10 - 1194 .View Article PubMed .Walker S , Monteil M , Phelan K , Lasserson TJ , Walters EH : Anti - IgE for chronic asthma in adults and children .", "label": "", "metadata": {}, "score": "73.63321"}
{"text": "10.1016/j.jaci.2011.06.015 .e2 PubMed Central PubMed .Gernez Y , Tirouvanziam R , Yu G , Ghosn EE , Reshamwala N , Nguyen T : Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy .", "label": "", "metadata": {}, "score": "73.66808"}
{"text": "Local : Injection site reaction ( 3 % ) .ALERT : U.S. Boxed Warning .Anaphylaxis : .Anaphylaxis , presenting as bronchospasm , hypotension , syncope , urticaria , and/or angioedema of the throat or tongue , has been reported to occur after administration of omalizumab .", "label": "", "metadata": {}, "score": "73.6779"}
{"text": "1135 - 1143 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Nonaka , A. Fukumoto , C. Ozu et al . , \" IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion , \" Acta Oto - Laryngologica , vol .", "label": "", "metadata": {}, "score": "73.74997"}
{"text": "Allergy testing .After 52 weeks of therapy , peanut - specific IgE ( PN - IgE ) did not change significantly ( Figure 5 ) .", "label": "", "metadata": {}, "score": "73.83207"}
{"text": "At the press conference , Genentech scientist Allen Kaplan , MD , a co - author on the NEJM report , said patients who do n't respond to antihistamines often are treated with corticosteroids or immunosuppressants such as cyclosporine .", "label": "", "metadata": {}, "score": "74.17229"}
{"text": "Corticosteroid reductions .Genentech examined reductions in corticosteroid use among subjects with inhaled only corticosteroid use at baseline using imputation of the last observation carried forward for those who discontinued ( Table 4 ) .", "label": "", "metadata": {}, "score": "74.25108"}
{"text": "Introduction .Patients with severe asthma often have a poor control of their disease ; they represent the subgroup that absorbs most of the costs [ 1 , 2 ] ; for these reasons it has given rise to the need to get new drugs able to improve control .", "label": "", "metadata": {}, "score": "74.3179"}
{"text": "Also , in this patient the contribution of placebo effects can not be excluded .However , improvements were seen in objective parameters such as lung function and number of exacerbations as well as symptom improvement .", "label": "", "metadata": {}, "score": "74.39226"}
{"text": "Antigen - specific IgE will appear in the serum following allergen sensitization .IgE may actually decrease somewhat at the time of allergen exposure during the allergen season for seasonal allergens , increase after the allergen season to 2 - 3 fold the pre - season baseline , then come back to baseline over the ensuing 2 - 3 months .", "label": "", "metadata": {}, "score": "74.48516"}
{"text": "Comments .Violations of run - in periods were the most common protocol violation in both trials .A too - brief run - in period could potentially have introduced uncertainty in the corticosteroid dosing at the start of the steroid stabilization period .", "label": "", "metadata": {}, "score": "74.56252"}
{"text": "As many as 5 allergens ( in 1:1:1:1:1 proportions ) could be included in an OIT treatment plan , provided all selected allergens met the inclusion criteria .", "label": "", "metadata": {}, "score": "74.62189"}
{"text": "Efficacy variables were defined for both the stable steroid and steroid reduction phases of the core period . \u00b7Primary endpoints : . -- number of exacerbations during the steroid reduction phase .", "label": "", "metadata": {}, "score": "74.697105"}
{"text": "B .Pregnancy Considerations .Adverse events have not been observed in animal reproduction studies .IgG molecules are known to cross the placenta .Patient Education .", "label": "", "metadata": {}, "score": "74.72764"}
{"text": "Treatment with an experimental , non - approved drug or investigational drugs within the past 30 days .Comments .The diagnosis of asthma in association with skin test reactivity to common allergens restricts the population to those with allergic asthma .", "label": "", "metadata": {}, "score": "74.79628"}
{"text": "Prior to reconstitution , store under refrigeration at 2 \u00b0 C to 8 \u00b0 C ( 36 \u00b0 F to 46 \u00b0 F ) ; product may be shipped at room temperature .", "label": "", "metadata": {}, "score": "74.80932"}
{"text": "Have patient report immediately to prescriber signs of infection , paresthesia , osteodynia , dyspnea , severe injection site irritation , angina , pain , syncope , dyspnea , edema , or hemoptysis ( HCAHPS ) .", "label": "", "metadata": {}, "score": "74.93111"}
{"text": "Endpoints were reasonable in that they were to collect clinically meaningful measures in asthma .Efficacy variables pertaining to corticosteroid reduction were repetitive , measuring slightly different aspects of the same effect .", "label": "", "metadata": {}, "score": "74.94926"}
{"text": "Subjects whose asthma is difficult to control were not studied in these trials .Demographic and baseline characteristics were well matched .Table 10 shows the numbers of subjects who completed trial 008 , and the reasons for dropping out .", "label": "", "metadata": {}, "score": "74.95235"}
{"text": "The primary endpoint of our investigation was safety ( i.e. the occurrence of allergic reactions throughout the course of the study ) .Methods .This open - label , phase 1 study was performed in a single center hospital setting , with Institutional Review Board ( IRB ) and Investigational New Drug ( IND ) approvals .", "label": "", "metadata": {}, "score": "75.0637"}
{"text": "Up to 8 % of the pediatric population suffers from food allergy and of those 30 % have clinical reactivity to more than one food allergen [ 1 - 3 ] .", "label": "", "metadata": {}, "score": "75.09532"}
{"text": "PubMed Central PubMed .Bedoret D , Singh AK , Shaw V , Hoyte EG , Hamilton R , DeKruyff RH : Changes in antigen - specific T - cell number and function during oral desensitization in cow 's milk allergy enabled with omalizumab .", "label": "", "metadata": {}, "score": "75.147415"}
{"text": "Participant selection .Specific food allergens that were eligible for inclusion in this trial included cow 's milk , egg , peanut , nuts , grains and sesame seed .", "label": "", "metadata": {}, "score": "75.154205"}
{"text": "Positive pregnancy test at time of initial screening .Medications which may impact the results of the ozone challenge , interfere with any other medications potentially used in the study ( to include steroids , beta antagonists , non - steroidal anti - inflammatory agents ) or suggest an ongoing illness ( such as antibiotics ) .", "label": "", "metadata": {}, "score": "75.21383"}
{"text": "A stepwise , conditional analysis of the two phases of the core period was to be performed .If the statistical criterion ( p - value of 0.05 on a 2-tailed test ) were met for analysis of the steroid reduction phase , the analysis would proceed for the stable steroid phase .", "label": "", "metadata": {}, "score": "75.278046"}
{"text": "urine pregnancy test if applicable .Day 2 ( Exposure to Air or 0.4 ppm Ozone for 2 hours ) : .Pre - challenge spirometry and symptom scoring ( SC ) and physical examination assessment ( Investigator MD ) ( 1 hr ) .", "label": "", "metadata": {}, "score": "75.33398"}
{"text": "World Allergy Organization Journal .Maurer M , Weller K , Bindslev - Jensen C , et al .Unmet clinical needs in chronic spontaneous urticaria .", "label": "", "metadata": {}, "score": "75.34146"}
{"text": "10.1016/j.anai.2010.03.015 .PubMed . de Boissieu D , Dupont C : Sublingual immunotherapy for cow 's milk protein allergy : a preliminary report .", "label": "", "metadata": {}, "score": "75.40505"}
{"text": "Other warnings / precautions : .Do not use to treat forms of urticaria other than chronic idiopathic urticaria .IgE levels remain elevated up to 1 year following treatment ; therefore , levels taken during treatment or for up to 1 year following treatment can not and should not be used as a dosage guide .", "label": "", "metadata": {}, "score": "75.82943"}
{"text": "d. \u00b3 12 % increase in FEV 1 over baseline value within 30 minutes of taking one or two puffs of albuterol ( 90 m g / puff ) .", "label": "", "metadata": {}, "score": "76.017624"}
{"text": "The lung function parameters were stable during the first months , showing a rise after four years .This could be explained by the bronchial remodelling caused by the long - standing ashtma , which needed several months of therapy to appreciate an improvement .", "label": "", "metadata": {}, "score": "76.17031"}
{"text": "--Infusions , every 2 weeks after the first week . --asthma and routine evaluations . --methacholine challenge at day 49 . --total and free serum IgE and product at days 7 , 21 , and 49 . \u00b7", "label": "", "metadata": {}, "score": "76.21911"}
{"text": "Airway reactivity is a measure of how sensitive the airways are to a medication used to diagnose asthma , called methacholine .We will examine these as additional information we can learn during the course of the study .", "label": "", "metadata": {}, "score": "76.33798"}
{"text": "Drug Interactions .Belimumab : Monoclonal Antibodies may enhance the adverse / toxic effect of Belimumab .Avoid combination .Loxapine : Agents to Treat Airway Disease may enhance the adverse / toxic effect of Loxapine .", "label": "", "metadata": {}, "score": "76.47886"}
{"text": "A 51-year - old woman had been receiving medical treatment for asthma since she was 21 years old .However , her asthma was poorly controlled despite treatment involving combination inhalation of high - dose corticosteroid and long - acting .", "label": "", "metadata": {}, "score": "76.49797"}
{"text": "Some previous research has found that omalizumab downregulates IgE receptor expression in basophils and also in mast cells .Kaplan said that it now appears that the disease is related to a non - IgE antibody that binds to the IgE receptor on these cells .", "label": "", "metadata": {}, "score": "76.49854"}
{"text": "10.1056/NEJMoa022613 .PubMed .Sampson HA , Leung DY , Burks AW , Lack G , Bahna SL , Jones SM : A phase II , randomized , doubleblind , parallelgroup , placebocontrolled oral food challenge trial of Xolair ( omalizumab ) in peanut allergy .", "label": "", "metadata": {}, "score": "76.57648"}
{"text": "Fever , arthralgia , and rash : Discontinue treatment if this constellation of symptoms occurs .Dosage adjustment in renal impairment : There are no dosage adjustments provided in the manufacturer 's labeling .", "label": "", "metadata": {}, "score": "76.98047"}
{"text": "10.1016/j.jaci.2010.02.029 .PubMed .Dello Iacono I , Tripodi S , Calvani M , Panetta V , Verga MC , Miceli SS : Specific oral tolerance induction with raw hen 's egg in children with very severe egg allergy : a randomized controlled trial .", "label": "", "metadata": {}, "score": "77.05246"}
{"text": "The maximum score is 9 , minimum is 0 .Exclusion criteria ( selected items ) .Previous treatment with rhuMAb - E25 or prior randomization into the trial .", "label": "", "metadata": {}, "score": "77.191605"}
{"text": "In order to evaluate the effectiveness at 32 weeks and at 3 years , we used the Global Evaluation of Treatment Effectiveness scale ( GETE )", "label": "", "metadata": {}, "score": "77.22814"}
{"text": "Genentech conducted an ANCOVA analysis on the intent - to - treat population , with last observation carried forward , as an exploratory analysis .Because this type of analysis is subject to less bias than the planned primary ( all subjects with at least 4 weeks of post - randomization data ) , it will be presented instead of the presented primary analysis .", "label": "", "metadata": {}, "score": "77.23984"}
{"text": "10.1111/j.1398 - 9995.2006.01196.x . PubMed .Longo G , Barbi E , Berti I , Meneghetti R , Pittalis A , Ronfani L : Specific oral tolerance induction in children with very severe cow 's milk - induced reactions .", "label": "", "metadata": {}, "score": "77.2688"}
{"text": "Recognition of worsenings of asthma and their management were critical to this trial .Subjects were to notify their investigator for evaluation for any of the following .", "label": "", "metadata": {}, "score": "77.297806"}
{"text": "The primary endpoint data , asthma symptom scores were recorded twice daily .Questions ( 16 for adults and 17 for adolescents ) asked about the major symptoms of asthma for both groups , and values ranged from 1 ( no symptom ) to 7 maximal symptom or all the time ) for each question ) .", "label": "", "metadata": {}, "score": "77.5757"}
{"text": "Following a report of an allergic reaction to food on a patient - reported questionnaire , the reaction is graded by the study coordinator or Principle Investigator .", "label": "", "metadata": {}, "score": "77.65199"}
{"text": "We used the Asthma Quality of Life Questionnaire ( AQLQ ) [ 8 ] to assess the patient 's QoL with an initial score of 1,71 points , indicating a poor HRQoL [ Table 1 ] .", "label": "", "metadata": {}, "score": "77.70108"}
{"text": "Keet CA , Frischmeyer - Guerrerio PA , Thyagarajan A , Schroeder JT , Hamilton RG , Boden S : The safety and efficacy of sublingual and oral immunotherapy for milk allergy .", "label": "", "metadata": {}, "score": "77.741104"}
{"text": "10.1016/S0091 - 6749(97)70028 - 9 .View Article PubMed .Beeh KM , Ksoll M , Buhl R : Elevation of total serum immunoglobulin E is associated with asthma in non allergic individuals .", "label": "", "metadata": {}, "score": "77.76634"}
{"text": "Oral , sublingual , and epicutaneous allergen - specific immunotherapies have been proposed as possible methods of desensitization for foods .Several prior studies have shown some success in using these approaches for single specific food allergens such as milk [ 8 - 15 ] , egg [ 13 , 14 , 16 - 18 ] , peanut [ 19 - 24 ] , and hazelnut [ 25 ] .", "label": "", "metadata": {}, "score": "77.93274"}
{"text": "Comments .It would have the effect in the analysis of highly weighting individuals who discontinued early in the trial .The observed maximum number of exacerbations in the stabilization period was about \u00bd the average of 1 every 2 weeks ( it was 3 , or an average of 1 every 4 weeks ) .", "label": "", "metadata": {}, "score": "77.99429"}
{"text": "10.1016/j.jaci.2012.05.038 .e5 PubMed Central PubMed .Babu KS , Polosa R , Morjaria JB : Anti - IgE - emerging opportunities for Omalizumab .", "label": "", "metadata": {}, "score": "78.08725"}
{"text": "FM coordinated diagnostic and therapeutic stages and was one of the principal contributors in writing the manuscript .RP contributed to the clinical approach , analyzed and interpreted the data and was a major contributor in writing the manuscript .", "label": "", "metadata": {}, "score": "78.1378"}
{"text": "10.1016/j.jaci.2012.11.011 .e1- 7 PubMed Central PubMed .Enrique E , Pineda F , Malek T , Bartra J , Basagana M , Tella R : Sublingual immunotherapy for hazelnut food allergy : a randomized , double - blind , placebo - controlled study with a standardized hazelnut extract .", "label": "", "metadata": {}, "score": "78.19124"}
{"text": "The evaluation is performed independently by both investigator and patient using the same 5 point scale .This scale ranges from excellent through good , moderate , and poor to worsening .", "label": "", "metadata": {}, "score": "78.24147"}
{"text": "Peanut was the most frequent food allergen determined in the 25 participants ( Additional file 1 : Tables S2 ) .Specific skin prick test ( peanut extract from Greer Laboratories , Lenoir , NC ) and serologies were compared at baseline and after a year of therapy .", "label": "", "metadata": {}, "score": "78.26923"}
{"text": "Institutional review board .mOIT : .Multiple allergen oral immunotherapy .PN - IgE : .Peanut specific Immunoglobulin E .PN - IgG4 : .", "label": "", "metadata": {}, "score": "78.411415"}
{"text": "Trials 008 and 009 enrolled a primarily adult Caucasian population of asthmatics of whom very few were in the geriatric age range .The proportions of subjects with hospital admissions and emergency room visits was low .", "label": "", "metadata": {}, "score": "78.42624"}
{"text": "3038.2012.01349.x .PubMed .Burks AW , Jones SM , Wood RA , Fleischer DM , Sicherer SH , Lindblad RW : Oral immunotherapy for treatment of egg allergy in children .", "label": "", "metadata": {}, "score": "78.47435"}
{"text": "10.1016/j.jaci.2011.10.023 .e1 - 5 PubMed Central PubMed .B\u00e9gin P , Wintheroth L , Dominguez T , Wilson SP , Bacal L , Mehrotra A : Safety and feasibility of oral immunotherapy to multiple allergens for food allergy .", "label": "", "metadata": {}, "score": "78.57602"}
{"text": "The presence of antigen - specific IgE is not sufficient to produce asthma .Persons with elevated serum IgE or skin reactions to allergens may not have asthma .", "label": "", "metadata": {}, "score": "78.60956"}
{"text": "Dose escalation .The participants returned to the CTFU every two weeks for a dose escalation visit with daily home diaries , which detailed any symptoms that occurred and treatments given during the daily home dosing for the prior 2 weeks .", "label": "", "metadata": {}, "score": "78.722115"}
{"text": "There is hypertrophy of airway smooth muscle .Asthma broadly can be characterized into childhood - onset and adult - onset disease .Childhood onset asthma is frequently found in children who are atopic , that is , with a genetic susceptibility to produce IgE toward common environmental antigens .", "label": "", "metadata": {}, "score": "78.73056"}
{"text": "Allergy Asthma Immunol Res .10.4168/aair.2013.5.1.3 .PubMed Central PubMed .Kim EH , Burks W : Managing food allergy in childhood .Curr Opin Pediatr .", "label": "", "metadata": {}, "score": "78.8271"}
{"text": "10.1016/j.jaci.2010.04.030 .e1PubMed .Clark AT , Islam S , King Y , Deighton J , Anagnostou K , Ewan PW : Successful oral tolerance induction in severe peanut allergy .", "label": "", "metadata": {}, "score": "78.87514"}
{"text": "The analysis was to be performed on subjects with at least 4 weeks of post - randomization data .Scores of the last week completed would be used for early dropouts .", "label": "", "metadata": {}, "score": "79.16497"}
{"text": "Table 2 .Trial Q0694 g : Demographics and baseline characteristics .The severity of some of the subjects was greater than that in the pivotal trials , since investigators felt the need for oral corticosteroid treatment , and medical care visits were greater in some .", "label": "", "metadata": {}, "score": "79.234215"}
{"text": "Christie L , Hine RJ , Parker JG , Burks W : Food allergies in children affect nutrient intake and growth .J Am Diet Assoc .", "label": "", "metadata": {}, "score": "79.25778"}
{"text": "A lunch will be provided and subjects will have time to eat during part of this study day .Methacholine challenge for NSBR ( 1 hr ) ( SC ) .", "label": "", "metadata": {}, "score": "79.37121"}
{"text": "4 , pp .456 - 461 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Iino , H. Nagamine , T. Yabe , and S. Matsutani , \" Eosinophils are activated in middle ear mucosa and middle ear effusion of patients with intractable otitis media associated with bronchial asthma , \" Clinical and Experimental Allergy , vol .", "label": "", "metadata": {}, "score": "79.51782"}
{"text": "Long - term controller medications include b -agonists , leukotriene antagonists , 5-lipoxygenase enzyme inhibitors , cromolyn sodium and nedocromil ; theophylline ; short term controller medications include b -agonists and ipratropium bromide .", "label": "", "metadata": {}, "score": "79.54802"}
{"text": "Inhalation of 99mTc labeled particles and baseline imaging for MCC and C / P ratio ( 30 minutes ) ( Dr Bennett and MCC technician ) .", "label": "", "metadata": {}, "score": "79.60581"}
{"text": "2010 , 125 ( 2 Supp 1 ) : AB22- .Casale TB , Busse WW , Kline JN , Ballas ZK , Moss MH , Townley RG : Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed - induced seasonal allergic rhinitis .", "label": "", "metadata": {}, "score": "79.71246"}
{"text": "The null hypothesis was to be tested on the mean score location shift .Most of the secondary analyses ( except for peak flow and spirometry ) were to be performed using the CMH statistic stratified by treatment schedule .", "label": "", "metadata": {}, "score": "79.75716"}
{"text": "10.1016/j.jaci.2013.09.046 .PubMed Central PubMed .Bock SA , Sampson HA , Atkins FM , Zeiger RS , Lehrer S , Sachs M : Double - blind , placebo - controlled food challenge ( DBPCFC ) as an office procedure : a manual .", "label": "", "metadata": {}, "score": "79.90636"}
{"text": "Use of daily theophylline within the past month .Pregnancy or nursing a baby .Nighttime symptoms of cough or wheeze greater than 1x / week at baseline ( not during a clearly recognized viral induced asthma exacerbation ) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma .", "label": "", "metadata": {}, "score": "80.07424"}
{"text": "10.1111/j.1398 - 9995.2004.00542.x .PubMed .Fisher HR , du Toit G , Lack G : Specific oral tolerance induction in food allergic children : is oral desensitisation more effective than allergen avoidance ? : a meta - analysis of published RCTs .", "label": "", "metadata": {}, "score": "80.12828"}
{"text": "The remaining 6 were started on their highest tolerated dose as their initial daily home doses .Participants reported 401 reactions per 7,530 home doses ( 5.3 % ) with a median of 3.2 reactions per 100 doses .", "label": "", "metadata": {}, "score": "80.170265"}
{"text": "Finally , it reviews information related to the asthma related clinical outcomes and to the severity of the asthma in subjects studied in the controlled trials .", "label": "", "metadata": {}, "score": "80.298"}
{"text": "PubMed Central PubMed .Fleischer DM , Burks AW , Vickery BP , Scurlock AM , Wood RA , Jones SM : Sublingual immunotherapy for peanut allergy : a randomized , double - blind , placebo - controlled multicenter trial .", "label": "", "metadata": {}, "score": "80.31903"}
{"text": "At this time , rush mOIT is an experimental treatment and should be conducted by trained research personnel with immediate access to emergency equipment .Phase 2 , blinded , multicenter trials are needed to continue to determine safety and efficacy parameters of rush mOIT in larger numbers of multi - sensitized participants .", "label": "", "metadata": {}, "score": "80.39564"}
{"text": "Table 1 shows a summary of the clinical trials that are suitable for a review of their effects on asthma symptomatology , exacerbations , and medication use .", "label": "", "metadata": {}, "score": "80.47398"}
{"text": "He was hospitalized in the Respiratory Department because of asthma exacerbation in 2004 and 2005 .The patient was not sensitized to aero- and food allergens and his respiratory symptoms were not affected by seasons .", "label": "", "metadata": {}, "score": "80.598724"}
{"text": "The first subject was recruited into trial 008 on February 9 , 1998 , and the last subject completed the trial on January 19 , 2000 .", "label": "", "metadata": {}, "score": "80.649216"}
{"text": "PubMed .Wang J , Visness CM , Sampson HA : Food allergen sensitization in inner - city children with asthma .J Allergy Clin Immunol .", "label": "", "metadata": {}, "score": "80.687935"}
{"text": "PubMed .Wang J : Management of the patient with multiple food allergies .Curr Allergy Asthma Rep. 2010 , 10 ( 4 ) : 271 - 277 .", "label": "", "metadata": {}, "score": "80.76033"}
{"text": "Thus this frequent violation would not have been expected to have an impact in the assessment of efficacy .Other violations with potential impact on the efficacy results of the trials were uncommon , so the impact on the overall results would have been expected to be small .", "label": "", "metadata": {}, "score": "80.829956"}
{"text": "Point out that the percentages of patients with at least one adverse event were similar in all treatment arms , although the number of patients who were treated was too small to draw any definitive safety conclusions .", "label": "", "metadata": {}, "score": "80.85113"}
{"text": "Discov Med .PubMed .Nurmatov U , Venderbosch I , Devereux G , Simons FE , Sheikh A : Allergen - specific oral immunotherapy for peanut allergy .", "label": "", "metadata": {}, "score": "80.92139"}
{"text": "All families and participants had 24-hour contact information for study personnel in case of an allergic reaction and/or questions at any point during the study .", "label": "", "metadata": {}, "score": "81.01076"}
{"text": "Number of Participants Experiencing One or More Protocol - defined Asthma Exacerbations During the Treatment Period [ Time Frame : Start of treatment to 24 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "81.03773"}
{"text": "2010 , 125 : AB216 - 10.1016/j.jaci.2009.07.002 .Food Allergy in Children and Young People : Diagnosis and Assessment of Food Allergy in Children and Young People in Primary Care and Community Settings .", "label": "", "metadata": {}, "score": "81.08728"}
{"text": "459 - 465 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Matsutani , T. Kobayashi , and T. Kousaka , \" Eosionophilic otitis media , \" Otolaryngology - Head and Neck Surgery , vol .", "label": "", "metadata": {}, "score": "81.42692"}
{"text": "FVC : .Forced Ventilatory Capacity .GETE : .Global Evaluation of Treatment Effectiveness .GINA : .Global Initiative for Asthma .IgE : .", "label": "", "metadata": {}, "score": "81.71924"}
{"text": "The pre - exacerbation dose of BDP could be instituted after control of asthma symptoms , at the discretion of the investigator .\u00b7 Subjects were to remain on the lowest dose of BDP tolerated without one of the above sentinel events for a minimum of 4 weeks prior to the end of the steroid reduction phase . \u00b7 Subjects unable to tolerate a steroid reduction were to remain at their baseline BDP dose .", "label": "", "metadata": {}, "score": "82.00065"}
{"text": "Varshney P , Jones SM , Scurlock AM , Perry TT , Kemper A , Steele P : A randomized controlled study of peanut oral immunotherapy : clinical desensitization and modulation of the allergic response .", "label": "", "metadata": {}, "score": "82.02763"}
{"text": "Reconstitution .Then gently swirl the upright vial for 5 to 10 seconds approximately every 5 minutes until dissolved ; generally takes 15 to 20 minutes to dissolve completely .", "label": "", "metadata": {}, "score": "82.05782"}
{"text": "10.1016/j.jaci.2011.01.051 .e1PubMed .Iyengar SR , Hoyte EG , Loza A , Bonaccorso S , Chiang D , Umetsu DT : Immunologic effects of omalizumab in children with severe refractory atopic dermatitis : a randomized , placebo - controlled clinical trial .", "label": "", "metadata": {}, "score": "82.157555"}
{"text": "EOM , first described by Matsutani et al . in 1995 [ 3 ] , is an intractable otitis media characterized by heavy eosinophilic infiltration and high viscous mucoid effusion , and it is found in patients with adult - onset asthma .", "label": "", "metadata": {}, "score": "82.22343"}
{"text": "Most subjects in both groups in both trials experienced no exacerbations ( see also comment under the review of different imputation analyses ) , so the treatment effect was seen in a relatively small number of subjects .", "label": "", "metadata": {}, "score": "82.27278"}
{"text": "PubMed Central PubMed .Park JH , Ahn SS , Sicherer SH : Prevalence of allergy to multiple versus single foods in a pediatric food allergy referral practice .", "label": "", "metadata": {}, "score": "82.33594"}
{"text": "FEV 1 . forced vital capacity , FVC .forced expiratory flow in the middle 50 % of expiration , FEF 25 - 75 . total asthma symptom score ( nocturnal + daytime + morning score ) .", "label": "", "metadata": {}, "score": "82.60384"}
{"text": "Sicherer SH , Noone SA , Munoz - Furlong A : The impact of childhood food allergy on quality of life .Ann Allergy Asthma Immunol .", "label": "", "metadata": {}, "score": "82.62074"}
{"text": "Secondary endpoints : .During stable steroid phase .number of subject experiencing at least one exacerbation .number of puffs of rescue medication .During steroid reduction phase .", "label": "", "metadata": {}, "score": "82.83193"}
{"text": "Casale and colleagues indicated in their NEJM report that the drug 's mechanism of action in chronic idiopathic urticaria remains uncertain .The disorder is not thought to be an IgE - mediated allergic condition .", "label": "", "metadata": {}, "score": "82.85501"}
{"text": "Subjects were to monitor their PEFR at home twice a day .In addition , the protocol instructed investigators to evaluate a subject for treatment if a subject were to have a \u00b3 20 % decrement in FEV 1 compared to the baseline measurement at visit 3 .", "label": "", "metadata": {}, "score": "82.86037"}
{"text": "Figure 1 shows this codification scheme .An individual should be assigned to the most severe grade in which any feature occurs .The characteristics noted in this figure are general and may overlap because asthma is highly variable .", "label": "", "metadata": {}, "score": "82.87272"}
{"text": "The patient tested negative for antineutrophil cytoplasmic antibodies ( ANCAs ) .Chest X - ray showed no abnormal findings .The patient had no symptoms indicative of allergic bronchopulmonary aspergillosis ( ABPA ) or Churg - Strauss syndrome .", "label": "", "metadata": {}, "score": "82.9827"}
{"text": "Acute , non - chronic , medical conditions , including ( but not limited to ) pneumonia or bronchitis requiring antibiotics , febrile illnesses , flu - like symptoms must be totally resolved symptomatically for 2 weeks .", "label": "", "metadata": {}, "score": "82.98437"}
{"text": "QoL : .Quality of Life .Declarations .Competing interests .FM participated in clinical trial for Novartis and received travel sponsorship from Novartis , Astra - Zeneca e Glaxo Smith - Kline .", "label": "", "metadata": {}, "score": "83.09105"}
{"text": "Completed core study , did not enter extension but completed follow - up period .Table 11 shows the numbers of subjects who completed trial 009 .", "label": "", "metadata": {}, "score": "83.11998"}
{"text": "Overnight observation in GCRC if needed ( for observation or treatment for adverse event as defined below under Safety Measures ) .( CEMALB nurse and Investigator MD ) .", "label": "", "metadata": {}, "score": "83.14713"}
{"text": "Warnings / Precautions .Concerns related to adverse effects : .Healthcare providers should be alert to eosinophilia , vasculitic rash , worsening pulmonary symptoms , cardiac complications , and/or neuropathy presenting in their patients .", "label": "", "metadata": {}, "score": "83.20473"}
{"text": "10.1111/j.1398 - 9995.2007.01501.x .PubMed .Dupont C , Kalach N , Soulaines P , Legoue - Morillon S , Piloquet H , Benhamou PH : Cow 's milk epicutaneous immunotherapy in children : a pilot trial of safety , acceptability , and impact on allergic reactivity .", "label": "", "metadata": {}, "score": "83.22439"}
{"text": "At the end of the run - in period , patients who continued to be symptomatic ( mean total symptom score \u00b3 3 on the last 14 days prior to Visit 3 ) would be randomized .", "label": "", "metadata": {}, "score": "83.265305"}
{"text": "Through Week 52 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "83.27737"}
{"text": "Decrements in either measure signify a worsening in the ability to exhale rapidly and completely , due in asthma to reversible obstruction of the airways .", "label": "", "metadata": {}, "score": "83.29303"}
{"text": "10.1016/j.jaci.2007.09.040 .PubMed .Skripak JM , Nash SD , Rowley H , Brereton NH , Oh S , Hamilton RG : A randomized , double - blind , placebo - controlled study of milk oral immunotherapy for cow 's milk allergy .", "label": "", "metadata": {}, "score": "83.38022"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "83.40968"}
{"text": "The variation that may be induced by other factors is also not well described ( e.g. , parasitic infection , other intercurrent illness , smoking , or environmental changes ) .", "label": "", "metadata": {}, "score": "83.48171"}
{"text": "Unspecified illnesses , which in the judgment of the investigator increase the risk associated with ozone inhalation challenge , will be a basis for exclusion .", "label": "", "metadata": {}, "score": "83.56849"}
{"text": "The NHLBI guidelines state that an individual should be assigned to the most severe grade in which a feature occurs .Another classification scheme , the GINA guidelines , classifies asthma as intermittent , mild persistent , moderate persistent , and severe persistent in terms of both asthma features and coincident treatment 2 .", "label": "", "metadata": {}, "score": "83.59877"}
{"text": "10.1016/j.jaci.2011.04.009 .PubMed Central PubMed .Klunker S , Saggar LR , Seyfert - Margolis V , Asare AL , Casale TB , Durham SR : Combination treatment with omalizumab and rush immunotherapy for ragweed - induced allergic rhinitis : Inhibition of IgE - facilitated allergen binding .", "label": "", "metadata": {}, "score": "83.61803"}
{"text": "PubMed Central PubMed .Leung DY , Sampson HA , Yunginger JW , Burks AW , Schneider LC , Wortel CH : Effect of anti - IgE therapy in patients with peanut allergy .", "label": "", "metadata": {}, "score": "83.71411"}
{"text": "10.1378/chest.10 - 0128 .View Article PubMed .Humbert M , Durham SR , Kimmitt P , Powell N , Assoufi B , Pfister R , Menz G , Kay AB , Corrigan CJ : Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non atopic subjects with asthma .", "label": "", "metadata": {}, "score": "83.792465"}
{"text": "Allergy 2011 ; 66 : 317 - 330 .Hongbo Y , Thomas CL , Harrison MA , Salek MS , Finlay AY , et . al .", "label": "", "metadata": {}, "score": "83.80592"}
{"text": "Have a history of upper respiratory infection or lower respiratory infection within the 30 days prior to randomization .Have a diagnosis of aspirin or nonsteroidal anti - inflammatory drug - induced asthma .", "label": "", "metadata": {}, "score": "83.901024"}
{"text": "10.1016/j.jaci.2009.03.045 . e1- 6 PubMed Central PubMed .Blumchen K , Ulbricht H , Staden U , Dobberstein K , Beschorner J , de Oliveira LC : Oral peanut immunotherapy in children with peanut anaphylaxis .", "label": "", "metadata": {}, "score": "84.0164"}
{"text": "When adult enrollment was exceeded , enrollment overall was stopped , although there was underenrollment in the adolescent and oral corticosteroid groups .Final enrollment was 317 .", "label": "", "metadata": {}, "score": "84.07864"}
{"text": "Patient should consult prescriber for additional questions .Intended Use and Disclaimer : Should not be printed and given to patients .This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient .", "label": "", "metadata": {}, "score": "84.25257"}
{"text": "Ozone : The 0.4 ppm ozone exposures will be conducted in an ozone exposure chamber .Each subject will be exposed to ozone for 2 hours .", "label": "", "metadata": {}, "score": "84.389725"}
{"text": "EOM occurs in conjunction with bronchial asthma , nasal polyps , or sinusitis .In particular , EOM is found in 90 % of patients with bronchial asthma [ 7 ] .", "label": "", "metadata": {}, "score": "84.59418"}
{"text": "In EOM cases , the biopsy of the middle ear mucous membrane shows eosinophilic infiltration , goblet cell metaplasia , granulation , and fibril formation in the epithelial and subepithelial parts .", "label": "", "metadata": {}, "score": "84.88878"}
{"text": "Allergens may induce bronchoconstriction in susceptible persons through an interaction with IgE. Other factors , not dependent upon an immediate reaction with IgE , may stimulate bronchoconstriction , for example , aspirin and other nonsteroidal anti - inflammatory drugs , exercise , cold air , and irritants .", "label": "", "metadata": {}, "score": "84.98926"}
{"text": "Rhonchi were heard from the right lung field .Hearing loss was profound in both ears .The patient was receiving 10 mg / day PSL ; no increase was observed in the peripheral blood eosinophil count .", "label": "", "metadata": {}, "score": "85.046295"}
{"text": "Exploratory variables ( during stable steroid phase only ) : . asthma - free days .An asthma - free day was defined as a day on which all of the following are met : . -- morning PEFR \u00b3 90 % of baseline ( mean of the 14 days prior to randomization ) .", "label": "", "metadata": {}, "score": "85.25308"}
{"text": "Sputum induction ( SC ) for assessment of pre - challenge differential cell counts , CD11b , cell identification markers , samples for mucus and mediator assessments ( 30 min ) .", "label": "", "metadata": {}, "score": "85.26352"}
{"text": "10.1016/j.jaci.2012.06.029 .PubMed .Gupta RS , Springston EE , Warrier MR , Smith B , Kumar R , Pongracic J : The prevalence , severity , and distribution of childhood food allergy in the United States .", "label": "", "metadata": {}, "score": "85.474594"}
{"text": "1401 Rockville Pike .Rockville , MD 20852 .Division of Clinical Trial Design and Analysis . HFM-576 .As a result of interactions between Genentech and CBER , Genentech submitted more clinical trial data in December 2002 .", "label": "", "metadata": {}, "score": "85.50008"}
{"text": "10.1016/j.jaci.2007.05.034 .PubMed .Parks KW , Casale TB : Anti - immunoglobulin E monoclonal antibody administered with immunotherapy .Allergy Asthma Proc .", "label": "", "metadata": {}, "score": "85.50192"}
{"text": "Peak expiratory flow rate ( PEFR ) may be used for home monitoring of obstruction of breathing ; in the clinic , expiratory volume in the first second of a forced expiration ( FEV 1 ) is determined .", "label": "", "metadata": {}, "score": "86.04339"}
{"text": "Statistical analysis .Food allergy testing results before and after therapy were compared with the Wilcoxon paired T test .All analyses were performed using GraphPad PRISM software version 6.0b ( GraphPad , LaJolla , CA ) .", "label": "", "metadata": {}, "score": "86.1519"}
{"text": "BDP .proportion of subjects with complete withdrawal of the dose of BDP .percent reduction in the dose of BDP .number of subjects with at least one asthma exacerbation .", "label": "", "metadata": {}, "score": "86.15523"}
{"text": "Most patients have the condition for far longer than 6 weeks .Casale and colleagues explained in the NEJM article that the usual duration is 1 to 5 years , lasting even longer in 11 % t0 14 % of patients .", "label": "", "metadata": {}, "score": "86.18074"}
{"text": "4611 Late Breaking Oral Abstract I. 25 March 2013 , 2:30 pm .S\u00e1nchez - Borges M , Asero R , Ansotegui IJ , et al .", "label": "", "metadata": {}, "score": "86.2852"}
{"text": "10.1016/j.jaci.2009.05.022 . e1 - 97 PubMed Central PubMed .Yu GP , Weldon B , Neale - May S , Nadeau KC : The safety of peanut oral immunotherapy in peanut - allergic subjects in a single - center trial .", "label": "", "metadata": {}, "score": "86.31642"}
{"text": "Have received chronic systemic corticosteroids ( oral or intravenous ) within 3 months or have received a burst of oral corticosteroids within the last 2 weeks prior to screening .", "label": "", "metadata": {}, "score": "86.37994"}
{"text": "10.1038/mi.2012.5 .PubMed Central PubMed .Savage JH , Courneya JP , Sterba PM , Macglashan DW , Saini SS , Wood RA : Kinetics of mast cell , basophil , and oral food challenge responses in omalizumab - treated adults with peanut allergy .", "label": "", "metadata": {}, "score": "86.44121"}
{"text": "PubMed .Nowak - Wegrzyn A , Sampson HA : Future therapies for food allergies .J Allergy Clin Immunol .10.1016/j.jaci.2010.12.1098 .quiz 74 - 5 PubMed Central PubMed .", "label": "", "metadata": {}, "score": "86.63141"}
{"text": "Other Study ID Numbers ICMJE . GCRC-2423 , HL080337 - 01 .Has Data Monitoring Committee .Yes .Plan to Share Data .Not Provided .", "label": "", "metadata": {}, "score": "86.647644"}
{"text": "Knowledge Center .Read our more detailed articles about specific areas of medicine , conditions , nutrition and forms of treatment .Abstract .Background .", "label": "", "metadata": {}, "score": "86.6985"}
{"text": "10.1056/NEJMoa1200435 .PubMed Central PubMed .Garcia Rodriguez R , Urra JM , Feo - Brito F , Galindo PA , Borja J , Gomez E : Oral rush desensitization to egg : efficacy and safety .", "label": "", "metadata": {}, "score": "86.7345"}
{"text": "daytime asthma symptom score . \u00b7Other variables .--Change from baseline in adult and pediatric asthma quality of life score ( activity limitations , . symptoms , emotional function , overall ) . --pharmacoeconomic variables .", "label": "", "metadata": {}, "score": "86.91149"}
{"text": "For subjects who discontinued during the stable steroid phase , exacerbations were attributed during the steroid reduction phase .The number of exacerbations attributed during the steroid reduction phase was the maximum observed for any subject during the steroid reduction phase + 1 . \u00b7", "label": "", "metadata": {}, "score": "86.92579"}
{"text": "Am Rev Respir Dis .View Article PubMed .Lloyd Andrew , Turk Florian , Leighton Trevor , Canonica GW : Psychometric evaluation of Global Evaluation of Treatment Effectiveness : a tool to assess patients with moderate - to - severe allergic asthma .", "label": "", "metadata": {}, "score": "86.94952"}
{"text": "Sputum induction for assessment of post - challenge cell differential counts , CD11b , cell identification markers , samples for mucus and mediator assessments ( 30 min ) ( SC ) .", "label": "", "metadata": {}, "score": "87.075485"}
{"text": "McGowan EC , Keet CA : Prevalence of self - reported food allergy in the National Health and Nutrition Examination Survey ( NHANES ) 2007 - 2010 .", "label": "", "metadata": {}, "score": "87.08702"}
{"text": "In that interval , there had been no exacerbations ; spirometry showed a slight worsening ( FEV1 1.33 l ) , while the AQLQ score was further improved ( 4.62 ) .", "label": "", "metadata": {}, "score": "87.17621"}
{"text": "The clinical meaning of changes in the asthma diary score ( the primary endpoint ) has not been established formally .Thus the clinical meaning of the primary endpoint results in this exploratory trial can be seen as suggestive only .", "label": "", "metadata": {}, "score": "87.54208"}
{"text": "The daytime asthma symptom score assessed the symptoms : shortness of breath , chest discomfort , wheezing , and cough over the previous 24 hour period on a scale of 0(no symptoms ) to 4(marked discomfort ) .", "label": "", "metadata": {}, "score": "87.71614"}
{"text": "She was treated with ear drops containing steroids ; however , her hearing loss gradually worsened .She was diagnosed with EOM because she had recurrent asthma attacks and otitis media with highly viscous middle ear effusion .", "label": "", "metadata": {}, "score": "87.792404"}
{"text": "Investigators uniformly answered the question about whether subjects were going to be exposed to a relevant allergen in the affirmative .Using the stratification of severity described for trial 008 the two treatment arms were well matched and very similar to those in trial 008 ( 22 % in the more severe category in both treatment arms ) .", "label": "", "metadata": {}, "score": "87.80995"}
{"text": "The trial was primarily adult , with 7 - 8 % adolescents .Investigators uniformly answered the question about whether subjects were going to be exposed to a relevant allergen in the affirmative .", "label": "", "metadata": {}, "score": "87.88182"}
{"text": "Comments .The criteria for subjects to notify investigators were rather complex .Case report forms , filled out at the treatment site , required that the site check whether one or more of these criteria was met .", "label": "", "metadata": {}, "score": "87.94466"}
{"text": "2011 , 128 ( 1 ) : e9-e17 .10.1542/peds.2011 - 0204 .PubMed .Gupta R , Holdford D , Bilaver L , Dyer A , Holl JL , Meltzer D : The economic impact of childhood food allergy in the United States .", "label": "", "metadata": {}, "score": "88.02393"}
{"text": "Week 13 : EXPOSURE PROCEDURES - SESSION 1 .Day 1 ( Pre - exposure ) : .Review medical history ( 30 min ) ( SC ) .", "label": "", "metadata": {}, "score": "88.18773"}
{"text": "Authors ' Affiliations .Department of Respiratory Diseases , Santa Maria Nuova Hospital .References .National Heart , and Blood Institute : Morbidity and mortality : 2002 .", "label": "", "metadata": {}, "score": "88.207954"}
{"text": "The safety endpoints assessed AEs , serious AEs ( SAEs ) , antibody data and changes in vital signs / laboratory evaluations .Efficacy endpoints included weekly itch severity , health - related quality of life , number of angioedema - free days , weekly hive scores ( number , size ) , reduction or elimination of disease symptoms ( itch , hives ) and the time it took to achieve a clinically significant benefit .", "label": "", "metadata": {}, "score": "88.611855"}
{"text": "CC received travel sponsorship from Nycomed , Astra - Zeneca .LZ received travel grant from Novartis , Astra - Zeneca , Glaxo Smith- Kline and participated in contracted research for Novartis , Glaxo Smith - Kline , Boehringer - Ingelheim .", "label": "", "metadata": {}, "score": "88.66627"}
{"text": "Symptom Score ( defined in section \" f \" ) no greater than 20 ( out of a possible 60 ) for total symptom score with a value no greater than 3 for any one score .", "label": "", "metadata": {}, "score": "88.7797"}
{"text": "10.1016/j.jaci.2013.07.018 .PubMed .Soller L , Ben - Shoshan M , Harrington DW , Fragapane J , Joseph L , St Pierre Y : Overall prevalence of self - reported food allergy in Canada .", "label": "", "metadata": {}, "score": "88.77986"}
{"text": "10.1016/S0002 - 8223(02)90351 - 2 . PubMed .Savage JH , Matsui EC , Skripak JM , Wood RA : The natural history of egg allergy .", "label": "", "metadata": {}, "score": "88.97609"}
{"text": "383 - 387 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Kawano , J. Ishitoya , and M. Tsukuda , \" Sinusitis with eosinophilic otitis media , \" Practica Oto - Rhino - Laryngologica , vol .", "label": "", "metadata": {}, "score": "88.97818"}
{"text": "10.1111/j.1365 - 2222.2005.02191.x .View Article PubMed .MacGlashan DW , Bochner BS , Adelman DC , Jardieu PM , Togias A , McKenzie - White J , Sterbinsky SA , Hamilton RG , Lichtenstein LM : Down - regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti - IgE antibody .", "label": "", "metadata": {}, "score": "89.28624"}
{"text": "Comments on conduct of the trial .In summary , the conduct of the trial was good , and will allow justifiable conclusions from a review of efficacy data as presented .", "label": "", "metadata": {}, "score": "89.41"}
{"text": "712 - 713 , 1995 .View at Google Scholar . Y. Iino , S. Tomioka - Matsutani , A. Matsubara , T. Nakagawa , and M. Nonaka , \" Diagnostic criteria of eosinophilic otitis media , a newly recognized middle ear disease , \" Auris Nasus Larynx , vol .", "label": "", "metadata": {}, "score": "89.606064"}
{"text": "UPDATE : This article , originally published on Feb. 24 , 2013 , was updated with new material on Feb. 25 at 9:00 a.m. .Several authors were employees of Genentech or Novartis .", "label": "", "metadata": {}, "score": "89.63342"}
{"text": "Table 12 and Table 13 show frequent and important protocol violations for the core and extension periods of trials 008 and 009 .Violations were summarized separately for the core and extension periods of trial 009 ; some of the subjects may have been the same as in the core period , potentially leading to redundancy in the table .", "label": "", "metadata": {}, "score": "89.7034"}
{"text": "Scores were collected daily .Change from Baseline ( mean of last 28 days prior to first dosing date ) at Week 24 ( mean of last 28 days prior to week 24 visit ) .", "label": "", "metadata": {}, "score": "89.79978"}
{"text": "Both .Ages .18 Years to 50 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "89.83351"}
{"text": "10.1016/j.jaci.2005.08.027 .PubMed .Gomez E , Mayorga C , Gomez F , Blazquez AB , Diaz - Perales A , Blanca M : Food allergy : management , diagnosis and treatment strategies .", "label": "", "metadata": {}, "score": "89.9513"}
{"text": "Week 16 : EXPOSURE PROCEDURES - SESSION 2 .Similar to Session 1 except with opposite ( air or ozone ) exposure regimen .Study Discontinuation Visit ( 5 - 10 days after last exposure ) History , spirometry ( SC ) , medical evaluation if needed ( Investigator MD ) .", "label": "", "metadata": {}, "score": "90.09396"}
{"text": "Inclusion Criteria : .Normal lung function , defined as ( Knudson 1976/1984 predicted set ) : .Evidence of allergy to house dust mite .", "label": "", "metadata": {}, "score": "90.20855"}
{"text": "Action Points .Some of these studies were published as abstracts and presented at a conference .These data and conclusions should be considered to be preliminary until published in a peer - reviewed journal .", "label": "", "metadata": {}, "score": "90.54636"}
{"text": "Healthcare providers should be prepared to administer appropriate therapy for managing potentially life - threatening anaphylaxis .Patients should be instructed on identifying signs / symptoms of anaphylaxis and to seek immediate care if they arise .", "label": "", "metadata": {}, "score": "90.96818"}
{"text": "If a female of childbearing potential , use an effective method of contraception ( in the opinion of the investigator ) to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study .", "label": "", "metadata": {}, "score": "91.19801"}
{"text": "715 - 724 , 2007 .View at Google Scholar \u00b7 View at Scopus Department of Health & Human Services Public Health Service .Food and Drug Administration .", "label": "", "metadata": {}, "score": "91.34488"}
{"text": "10.1016/j.iac.2011.11.004 .PubMed .Yang YH , Chiang BL : Novel approaches to food allergy .Clin Rev Allergy Immunol .2013 , EPub Jan 18 2013 .", "label": "", "metadata": {}, "score": "91.3609"}
{"text": "The primary endpoint analysis included imputations for subjects who discontinued prematurely .The imputation technique was as follows : . \u00b7For subjects who discontinued during a phase , the number of exacerbations attributed to the subject during that phase was the number experienced + the number of days remaining in the period divided by 14 .", "label": "", "metadata": {}, "score": "91.52223"}
{"text": "Missing data from diaries ( BDP use , peak flows , symptom data ) and spirometry data were not to be imputed .The pretreatment average from the last 14 days prior to visit 3 ( baseline ) was used as the baseline for diary data , except for BDP use , where the pretreatment , visit 3 dose was considered baseline .", "label": "", "metadata": {}, "score": "91.559975"}
{"text": "Administrative problems predominated reasons for failure to complete the extension period .Although not directly pertinent to the evaluation of efficacy , it should be noted that more subjects completed their follow - up examination than completed the extension phase .", "label": "", "metadata": {}, "score": "91.586136"}
{"text": "Improved hearing has been maintained ( Figure 1 ) .Amelioration of both asthma symptoms and hearing has contributed to a better quality of life ( QOL ) of the patient .", "label": "", "metadata": {}, "score": "91.87316"}
{"text": "KN conceived and designed the study .PB , TD , LB , TT , BK , AM , AB , SS , GO and MW assessed the patient and acquired clinical data .", "label": "", "metadata": {}, "score": "92.1113"}
{"text": "Approximately 25 - 30 % of these cases were in persons less than 15 years old .Asthma can also be a mortal condition .In 1999 , asthma was responsible for about 4600 deaths ( about 4 % of these in persons less than 15 years old ) .", "label": "", "metadata": {}, "score": "92.35573"}
{"text": "10.1111/j.1398 - 9995.2009.01982.x .PubMed .Jones SM , Pons L , Roberts JL , Scurlock AM , Perry TT , Kulis M : Clinical efficacy and immune regulation with peanut oral immunotherapy .", "label": "", "metadata": {}, "score": "92.69211"}
{"text": "Obstruction to the outflow of air from the lungs , due to bronchoconstriction , occurs variably within an individual , and may reverse spontaneously or with treatment .", "label": "", "metadata": {}, "score": "92.71448"}
{"text": "Exclusion Criteria : .A history of significant chronic illnesses ( to include diabetes , autoimmune diseases , immunodeficiency state , known ischemic heart disease , chronic respiratory diseases such as chronic obstructive pulmonary disease or severe asthma , hypertension ) .", "label": "", "metadata": {}, "score": "92.75705"}
{"text": "Asthma : . 1 % to 10 % : .Central nervous system : Pain ( 7 % ) , dizziness ( 3 % ) , fatigue ( 3 % ) .", "label": "", "metadata": {}, "score": "92.92439"}
{"text": "CC was a contributor in writing the manuscript .AS was a contributor in writing the manuscript .LZ was a contributor in writing the manuscript and he gave final approval of the version to be published .", "label": "", "metadata": {}, "score": "92.95915"}
{"text": "Table 14 .Trial 009 .Table 15 shows exacerbations as determined in trial 009 using the protocol - defined technique of imputation .Table 15 .", "label": "", "metadata": {}, "score": "93.70163"}
{"text": "Case Report .A 51-year - old woman presented with chief complaints of wheezing and hearing loss .She was a nonsmoker with a history of allergic rhinitis .", "label": "", "metadata": {}, "score": "93.93147"}
{"text": "Subjects recall their experiences during the previous 2 weeks and score a number of asthma - related problems on a 7-point scale from 1 ( maximum impairment ) to 7 ( no impairment ) .", "label": "", "metadata": {}, "score": "94.15888"}
{"text": "We want to learn if chronic allergic response , known as \" IgE - induced airway inflammation \" is what causes the increased inflammation in response to ozone .", "label": "", "metadata": {}, "score": "95.0235"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .The authors have no relevant conflict of interest to disclose .", "label": "", "metadata": {}, "score": "95.2253"}
{"text": "10.1111/j.1365 - 2222.2011.03722.x .PubMed .Hofmann AM , Scurlock AM , Jones SM , Palmer KP , Lokhnygina Y , Steele PH : Safety of a peanut oral immunotherapy protocol in children with peanut allergy .", "label": "", "metadata": {}, "score": "95.38454"}
{"text": "European Lung White Book : The first comprehensive survey on respiratory health in Europe .European Respiratory Society .Edited by : Loddenkemper R , Gibson GJ , Sybille Y. 2003 , Sheffield : ERSJ , 16 - 25 .", "label": "", "metadata": {}, "score": "95.40556"}
{"text": "During this hospital stay , were you given any medicine that you had not taken before ?Before giving you any new medicine , how often did hospital staff tell you what the medicine was for ?", "label": "", "metadata": {}, "score": "95.53276"}
{"text": "To view content sources and attributions , please refer to our editorial policy .Current Primary Outcome Measures ICMJE ( submitted : February 5 , 2008 ) .", "label": "", "metadata": {}, "score": "95.73751"}
{"text": "Chronic idiopathic urticaria is seen in about one in 100 to 200 adults and is a serious problem for those patients afflicted with it .To qualify for a diagnosis , patients must have itchy welts lasting for at least 6 weeks with no obvious cause such as reaction to a known allergen .", "label": "", "metadata": {}, "score": "95.780426"}
{"text": "Allergic asthma is an IgE - mediated atopic disease that , in susceptible individuals , causes recurrent episodes of wheezing , breathlessness , chest tightness , and cough , particularly at night and in the early morning .", "label": "", "metadata": {}, "score": "95.87854"}
{"text": "Lung function tests showed a severe obstruction : FEV1 1.52 ( 46 % of predicted ) and FEV1/FVC 0.41 [ Table 1 ] .", "label": "", "metadata": {}, "score": "95.91251"}
{"text": "About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "95.94522"}
{"text": "Primarily via hepatic degradation ; intact IgG may be secreted in bile .Time to Peak . 7 - 8 days .Half - Life Elimination .", "label": "", "metadata": {}, "score": "96.75702"}
{"text": "Abnormal chest X - ray ( excluding changes consistent with asthma ) within the last 12 months of Visit 1 .Significant systemic disease , or a history of such disease ( e.g. , cancer , infection , hematological , renal , hepatic , coronary heart disease or other cardiovascular diseases , endocrinologic , or gastrointestinal disease ) within the previous 3 months .", "label": "", "metadata": {}, "score": "97.40988"}
{"text": "We thank Dr. Sharon Chinthrajah for the reading and editing of the manuscript .Funding .Funding for this study was provided by philanthropy and by the Fund for Food Allergy Research at Stanford .", "label": "", "metadata": {}, "score": "97.9731"}
{"text": "a. Meet standards of the American Thoracic Society .b. A positive prick skin test ( e.g. , +3 reaction ) to at least one of the following allergens to which patients are exposed to during the trial : Dermatophagoides farinae , Dermatophagoides pteronyssinus , cockroaches ( whole body ) , dog or cat .", "label": "", "metadata": {}, "score": "98.01741"}
{"text": "We would like to thank members of the DSMB for their review of the safety data .Philippe B\u00e9gin MD , FRCPC was supported by AllerGen NCE Inc. ( the Allergy , Gene and Environment Network ) , a member of the Networks of Centre of Excellence Canada program .", "label": "", "metadata": {}, "score": "98.25785"}
{"text": "-- a \u00b3 50 % increase in 24-hour rescue medication use on \u00b3 2 of 3 successive days , .compared to the last week prior to randomization ( must exceed 8 puffs ) .", "label": "", "metadata": {}, "score": "98.39908"}
{"text": "SPT : .Skin prick test .Declarations .Acknowledgement .The authors would like to acknowledge Bruce Barnett , PhD and Jelena Berglund , PhD for their review of good manufacturing practices .", "label": "", "metadata": {}, "score": "98.79784"}
{"text": "Interventional .Study Phase .Not Provided .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "98.935974"}
{"text": ", 2 Jul. 2013 .Web .10 Feb. 2016 .Contact our news editors .For any corrections of factual information , or to contact our editorial team , please see our contact page .", "label": "", "metadata": {}, "score": "99.22509"}
{"text": "Hearing loss and otorrhea appeared at the age of 44 , and she was given a diagnosis of eosinophilic otitis media ( EOM ) and received medical treatment .", "label": "", "metadata": {}, "score": "99.54942"}
{"text": "MedPageToday is a trusted and reliable source for clinical and policy coverage that directly affects the lives and practices of health care professionals .Physicians and other healthcare professionals may also receive Continuing Medical Education ( CME ) and Continuing Education ( CE ) credits at no cost for participating in MedPage Today - hosted educational activities .", "label": "", "metadata": {}, "score": "99.59201"}
{"text": "There were 27 sites in trial Q0694 g , with no one site or small number of sites dominating enrollment .The largest site enrollment , for one site , was 27 there were 12 sites whose enrollment was between 10 - 20 subjects inclusive , and 14 in which site enrollment was between 6 and 9 subjects inclusive .", "label": "", "metadata": {}, "score": "101.19474"}
{"text": "10.1016/j.jim.2005.06.008 .View Article PubMed .Copyright .\u00a9 Menzella et al ; licensee BioMed Central Ltd. 2011 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "104.679794"}
{"text": "Received 24 September 2012 ; Accepted 30 October 2012 .Academic Editors : J. Bordon , W. Gao , T. Kawashima , and W. Rodriguez .", "label": "", "metadata": {}, "score": "104.78692"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "105.69211"}
{"text": "Neuromuscular & skeletal : Arthralgia ( 8 % ) , leg pain ( 4 % ) , arm pain ( 2 % ) , bone fracture ( 2 % ) .", "label": "", "metadata": {}, "score": "106.66431"}
{"text": "Not Provided .Responsible Party .Barbara Longmire , Director Office of Clinical Trials , University of North Carolina at Chapel Hill --- Our top categories - Alzheimer 's / Dementia - Breast Cancer - Cancer / Oncology - Diabetes - Ebola - HIV / AIDS - Infectious Diseases - Multiple Sclerosis - Nutrition / Diet - Parkinson 's Disease - Stem Cell Research --- View all categories .", "label": "", "metadata": {}, "score": "107.070114"}
{"text": "Allergy , Immunology , and Rheumatology Division , Stanford University .Dermatology , Allergy and Clinical Immunology Reference Laboratory , Johns Hopkins University School of Medicine .", "label": "", "metadata": {}, "score": "107.334625"}
{"text": "2006 , CD003559 - 2 .GINA Global Strategy for Asthma Management and Prevention , 2006 NHI Publications No 02 - 3659 .GINA update .", "label": "", "metadata": {}, "score": "111.80896"}
{"text": "Return next morning for 30 min gamma camera scan .( Dr Bennett and MCC technician ) .Symptom scoring and dismiss home ( SC ) , Physical assessment .", "label": "", "metadata": {}, "score": "112.52767"}
{"text": "10.1016/j.jaci.2010.12.1111 .PubMed Central PubMed .Copyright .\u00a9 B\u00e9gin et al . ; licensee BioMed Central Ltd. 2014 .This article is published under license to BioMed Central Ltd. Abstract .", "label": "", "metadata": {}, "score": "114.234924"}
{"text": "This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "114.802444"}
{"text": "For more information , please read our terms of use .Copyright Medical News Today : Excluding email / sharing services explicitly offered on this website , material published on Medical News Today may not be reproduced , or distributed without the prior written permission of Medilexicon International Ltd.", "label": "", "metadata": {}, "score": "122.16574"}
{"text": "All rights reserved .The material on this site is for informational purposes only , and is not a substitute for medical advice , diagnosis or treatment provided by a qualified health care provider .", "label": "", "metadata": {}, "score": "123.269455"}
{"text": "_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ .", "label": "", "metadata": {}, "score": "133.3303"}
